NE Axis Probes and Cross-Links — Annotated Entries (P5-P14)

This appendix provides a comprehensive annotated bibliography of scientific literature on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Sources are organized by research domain and include full identifying information where available. It serves as the citation-level companion to the evidence synthesized in Part IV (Research and Evidence Synthesis, opening at Chapter ME/CFS-Specific Research Methods).

1 Hartwig et al. 2020 — Attenuated beta2-Adrenergic IgG Activation in ME/CFS

*Full Citation:*: Hartwig J, Sotzny F, Bauer S, Heidecke H, Riemekasten G, Dragun D, Meisel C, Dames C, Grabowski P, Scheibenbogen C. IgG stimulated beta2 adrenergic receptor activation is attenuated in patients with ME/CFS. *Brain, Behavior, & Immunity - Health*. 2020;3:100047. [@Hartwig2020Beta2AdrenergicIgG]
*DOI:*: [10.1016/j.bbih.2020.100047](https://doi.org/10.1016/j.bbih.2020.100047)
*PMID:*: 34589837
*Key Findings:*:
    - ME/CFS patient IgG changed beta2-adrenergic receptor activation in a cell-based bioassay relative to controls.
    - Supports an autoantibody-mediated adrenergic signalling defect upstream of the central NE deficit.
*Conclusion:* An adrenergic-receptor-directed autoimmune candidate fits the "upstream cause" arm; assay is a candidate stratification tool.
*Limitations:* Single centre (Charité Berlin); bioassay readout, not in-vivo receptor occupancy; not independently replicated.
*Certainty Assessment:* 0.70 raw x 1.00 (ME/CFS cohort) = *discounted 0.70*

2 Hall et al. 2022 — GPCR Autoantibodies in POTS (Standard Methodology)

*Full Citation:*: Hall J, Bourne KM, Vernino S, Hamrefors V, Kharraziha I, Nilsson J, Sheldon RS, Fedorowski A, Raj SR. Detection of G Protein-Coupled Receptor Autoantibodies in Postural Orthostatic Tachycardia Syndrome Using Standard Methodology. *Circulation*. 2022;146(8):613-622. [@Hall2022GPCRAutoantibodiesPOTS]
*DOI:*: [10.1161/CIRCULATIONAHA.122.059971](https://doi.org/10.1161/CIRCULATIONAHA.122.059971)
*PMID:*: 35766055
*Key Findings:*:
    - NULL study. Autoantibody concentrations to 11 cardiovascular GPCRs (adrenergic, muscarinic) did NOT differ between 116 POTS patients and 81 healthy controls; ROC discrimination was poor.
    - Nearly all POTS patients (98.3%) and all controls (100%) were above the manufacturer's alpha1-adrenergic seropositive threshold, indicating the threshold is not disease-specific.
*Conclusion:* This is NEGATIVE evidence: standard ELISA GPCR-autoantibody tests did not distinguish POTS from controls and "are not useful for establishing the role of autoimmunity in POTS." It does NOT support an adrenergic-autoantibody upstream cause; it constrains it.
*Limitations:* POTS, not ME/CFS; ELISA methodology may miss functional antibodies (a competing explanation); single assay platform.
*Certainty Assessment:* 0.70 raw x 0.80 (POTS comorbid condition) = *discounted 0.56 — but this certainty applies to the NULL finding, not to the presence of autoantibodies.*

3 Senard and Rouet 2006 — Dopamine beta-Hydroxylase Deficiency

*Full Citation:*: Senard JM, Rouet P. Dopamine beta-hydroxylase deficiency. *Orphanet Journal of Rare Diseases*. 2006;1:7. [@Senard2006DBHdeficiency]
*DOI:*: [10.1186/1750-1172-1-7](https://doi.org/10.1186/1750-1172-1-7)
*PMID:*: 16722595
*Key Findings:*:
    - Congenital DBH deficiency abolishes norepinephrine/epinephrine with preserved dopamine.
    - Produces profound orthostatic hypotension and noradrenergic failure.
*Conclusion:* Human inborn-error proof that a selective NE deficit with intact DA is biologically coherent — the exact pattern Aregawi 2026 reports.
*Limitations:* Rare monogenic disease; not ME/CFS; no fatigue-outcome data.
*Certainty Assessment:* 0.80 raw x 0.50 (other disease model) = *discounted 0.40*

4 Lutsenko et al. 2019 — Copper and the Brain Noradrenergic System

*Full Citation:*: Lutsenko S, Washington-Hughes C, Ralle M, Schmidt K. Copper and the brain noradrenergic system. *Journal of Biological Inorganic Chemistry*. 2019;24(8):1179-1188. [@Lutsenko2019CopperNoradrenergic]
*DOI:*: [10.1007/s00775-019-01737-3](https://doi.org/10.1007/s00775-019-01737-3)
*PMID:*: 31691104
*Key Findings:*:
    - DBH is a copper-dependent enzyme; brain copper handling constrains NE synthesis.
*Conclusion:* Adds copper status to the upstream-causes list for a selective NE deficit — a standard, checkable lab.
*Limitations:* Review; no ME/CFS copper data.
*Certainty Assessment:* 0.65 raw x 0.75 (general biology) = *discounted 0.49*

5 Hahn et al. 2003 — SLC6A2 (NET) Mutation and Orthostatic Intolerance

*Full Citation:*: Hahn MK, Robertson D, Blakely RD. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. *The Journal of Neuroscience*. 2003;23(11):4470-4478. [@Hahn2003SLC6A2NET]
*DOI:*: [10.1523/JNEUROSCI.23-11-04470.2003](https://doi.org/10.1523/JNEUROSCI.23-11-04470.2003)
*PMID:*: 12805287
*Key Findings:*:
    - A dominant-negative NET mutation reduces surface transporter and is linked to orthostatic intolerance.
*Conclusion:* Genetic evidence that altered NE reuptake capacity produces an autonomic phenotype; supports NET as both a mechanism and a drug target.
*Limitations:* Single family; in-vitro transporter assay; not ME/CFS.
*Certainty Assessment:* 0.65 raw x 0.50 (other disease model) = *discounted 0.33*

6 Rivera et al. 2017 — BH4 Deficiency Amplifies Inflammation

*Full Citation:*: Rivera JC, Noueihed B, Madaan A, Lahaie I, Pan J, Belik J, Chemtob S. Tetrahydrobiopterin (BH4) deficiency is associated with augmented inflammation and microvascular degeneration in the retina. *Journal of Neuroinflammation*. 2017;14(1):181. [@Rivera2017BH4deficiency]
*DOI:*: [10.1186/s12974-017-0955-x](https://doi.org/10.1186/s12974-017-0955-x)
*PMID:*: 28874201
*Key Findings:*:
    - BH4 depletion augments inflammation and microvascular degeneration.
*Conclusion:* Links cofactor depletion (a TH/DBH constraint) to neuroinflammation — two upstream causes can reinforce each other.
*Limitations:* Animal/retina model; translation gap to human brain.
*Certainty Assessment:* 0.55 raw x 0.50 (animal model) = *discounted 0.28*

7 Rangaraju et al. 2014 — Activity-Driven Local ATP Synthesis Required for Synaptic Function

*Full Citation:*: Rangaraju V, Calloway N, Ryan TA. Activity-driven local ATP synthesis is required for synaptic function. *Cell*. 2014;156(4):825-835. [@Rangaraju2014ActivityDrivenATPsynapse]
*DOI:*: [10.1016/j.cell.2013.12.042](https://doi.org/10.1016/j.cell.2013.12.042)
*PMID:*: 24529383
*Key Findings:*:
    - Synaptic vesicle cycling requires local, activity-driven ATP synthesis; ATP shortage impairs release.
*Conclusion:* Mechanistic foundation for "low ATP selectively impairs ATP-dependent vesicular NE release" — the paper's core upstream energy claim.
*Limitations:* In-vitro/animal neurons; not noradrenergic-specific; not ME/CFS.
*Certainty Assessment:* 0.75 raw x 0.40 (in vitro) = *discounted 0.30*

8 Arnsten et al. 2023 — alpha2A Agonists for Neuroinflammatory Cognitive Disorders

*Full Citation:*: Arnsten AFT, Ishizawa Y, Xie Z. Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. *Molecular Psychiatry*. 2023;28(11):4540-4552. [@Arnsten2023Alpha2ANeuroinflammatory]
*DOI:*: [10.1038/s41380-023-02057-4](https://doi.org/10.1038/s41380-023-02057-4)
*PMID:*: 37029295
*Key Findings:*:
    - Postsynaptic alpha2A agonists strengthen prefrontal noradrenergic signalling under neuroinflammatory conditions without suppressing LC firing.
*Conclusion:* Mechanistic rationale for guanfacine as a medication that raises PFC NE signal without worsening the central NE deficit.
*Limitations:* Review/rationale; no ME/CFS trial.
*Certainty Assessment:* 0.60 raw x 0.75 (general population) = *discounted 0.45*

9 Osorio-Forero et al. 2021 — Noradrenergic Control of NREM Sleep Substates

*Full Citation:*: Osorio-Forero A, Cardis R, Vantomme G, Guillaume-Gentil A, Katsioudi G, Devenoges C, Fernandez LMJ, Luthi A. Noradrenergic circuit control of non-REM sleep substates. *Current Biology*. 2021;31(22):5009-5023.e7. [@OsorioForero2021NoradrenergicNREM]
*DOI:*: [10.1016/j.cub.2021.09.041](https://doi.org/10.1016/j.cub.2021.09.041)
*PMID:*: 34648731
*Key Findings:*:
    - Locus coeruleus NE activity sets NREM sleep substates and infraslow oscillations.
*Conclusion:* Downstream consequence: low LC-NE output is a candidate mechanism for unrefreshing sleep independent of sleep architecture.
*Limitations:* Animal circuit study; not ME/CFS.
*Certainty Assessment:* 0.75 raw x 0.50 (animal model) = *discounted 0.38*

10 Luthi and Nedergaard 2025 — Microarousals, Noradrenaline, and Sleep Function

*Full Citation:*: Luthi A, Nedergaard M. Anything but small: Microarousals stand at the crossroad between noradrenaline signaling and key sleep functions. *Neuron*. 2025;113(4):509-523. [@Luthi2025MicroarousalsNoradrenaline]
*DOI:*: [10.1016/j.neuron.2024.12.009](https://doi.org/10.1016/j.neuron.2024.12.009)
*PMID:*: 39809276
*Key Findings:*:
    - Noradrenergic microarousals are coupled to glymphatic clearance and memory consolidation.
*Conclusion:* Ties the NE deficit to the clearance and sleep-refresh consequences the paper already models.
*Limitations:* Review; causal direction of NE-clearance coupling still debated.
*Certainty Assessment:* 0.60 raw x 0.75 (general population) = *discounted 0.45*

11 Hayashida and Obata 2019 — Descending Noradrenergic Inhibitory System in Chronic Pain

*Full Citation:*: Hayashida K, Obata H. Strategies to Treat Chronic Pain and Strengthen Impaired Descending Noradrenergic Inhibitory System. *International Journal of Molecular Sciences*. 2019;20(4):822. [@Hayashida2019DescendingNoradrenergic]
*DOI:*: [10.3390/ijms20040822](https://doi.org/10.3390/ijms20040822)
*PMID:*: 30769838
*Key Findings:*:
    - Descending noradrenergic inhibition (alpha2) is a therapeutic lever in chronic pain.
*Conclusion:* Downstream consequence: low central NE disinhibits pain pathways — a mechanistic account of the pain-fatigue overlap.
*Limitations:* Review; not ME/CFS-specific.
*Certainty Assessment:* 0.60 raw x 0.75 (general population) = *discounted 0.45*

12 Feng et al. 2024 — GRAB(NE) Sensors for In-Vivo Norepinephrine Monitoring

*Full Citation:*: Feng J, Dong H, Lischinsky JE, Zhou J, Deng F, Zhuang C, Miao X, Wang H, Li G, Cai R, Xie H, Cui G, Lin D, Li Y. Monitoring norepinephrine release in vivo using next-generation GRAB(NE) sensors. *Neuron*. 2024;112(12):1930-1942.e6. [@Feng2024GRABneSensors]
*DOI:*: [10.1016/j.neuron.2024.03.001](https://doi.org/10.1016/j.neuron.2024.03.001)
*PMID:*: 38547869
*Key Findings:*:
    - Genetically encoded NE sensors enable direct in-vivo measurement of noradrenergic release.
*Conclusion:* A measurement tool that could, in principle, test the central NE deficit without lumbar puncture.
*Limitations:* Animal/tool development; no human ME/CFS use yet.
*Certainty Assessment:* 0.75 raw x 0.50 (animal model) = *discounted 0.38*

13 Ahmad et al. 2026 — Locus Coeruleus at the Crossroads of Inflammation and Neurodegeneration

*Full Citation:*: Ahmad I, Alemani R, Feinstein DL. The locus coeruleus at the crossroads of inflammation and neurodegeneration in multiple sclerosis. *Journal of Neuroinflammation*. 2026;23(1). [@Ahmad2026LocusCoeruleusMS]
*DOI:*: [10.1186/s12974-026-03981-2](https://doi.org/10.1186/s12974-026-03981-2)
*PMID:*: 42711720
*Key Findings:*:
    - LC is an inflammation-vulnerable noradrenergic hub in MS.
*Conclusion:* Cross-disease analogue: neuroinflammation targeting the LC is a plausible upstream cause of a central NE deficit.
*Limitations:* MS, not ME/CFS; review; no LC imaging in ME/CFS.
*Certainty Assessment:* 0.50 raw x 0.50 (other disease model) = *discounted 0.25*

14 Cipriani et al. 2018 — 21 Antidepressants Network Meta-analysis

*Full Citation:*: Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *The Lancet*. 2018;391(10128):1357-1366. [@Cipriani2018AntidepressantsNMA]
*DOI:*: [10.1016/S0140-6736(17)32802-7](https://doi.org/10.1016/S0140-6736(17)32802-7)
*PMID:*: 29477251
*Key Findings:*:
    - All antidepressants beat placebo, but reboxetine was among the least efficacious agents and had the highest dropout rates.
*Conclusion:* A direct caution on selective-NRI repurposing for ME/CFS — weak efficacy and poor tolerability in the best-powered comparison available.
*Limitations:* Major depressive disorder, not ME/CFS; surrogate endpoints; industry data.
*Certainty Assessment:* 0.85 raw x 0.75 (general population) = *discounted 0.64*

15 Migliorini et al. 2023 — Duloxetine for Fibromyalgia

*Full Citation:*: Migliorini F, Maffulli N, Eschweiler J, Baroncini A, Tingart M, Colarossi G. Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis. *Journal of Orthopaedic Surgery and Research*. 2023;18(1):504. [@Migliorini2023DuloxetineFM]
*DOI:*: [10.1186/s13018-023-03995-z](https://doi.org/10.1186/s13018-023-03995-z)
*PMID:*: 37461044
*Key Findings:*:
    - 11 RCTs, n=3432: duloxetine beat placebo on pain/fatigue across doses; discontinuations fewer at 30 mg.
*Conclusion:* The strongest positive human signal in the noradrenergic set, but in fibromyalgia — supports SNRIs for the pain-fatigue overlap, not for ME/CFS fatigue specifically.
*Limitations:* Fibromyalgia, mostly women; not ME/CFS.
*Certainty Assessment:* 0.75 raw x 0.80 (comorbid condition) = *discounted 0.60*

16 Cruccioli et al. 2026 — Amantadine for MS Fatigue (negative)

*Full Citation:*: Cruccioli MM, Carneiro PHT, Pitanga JFJ, Rossi YI, et al. Amantadine for multiple sclerosis-related fatigue: a systematic review and meta-analysis of randomized controlled trials. *Neurodegenerative Disease Management*. 2026;16(5):643-649. [@Cruccioli2026AmantadineMSfatigue]
*DOI:*: [10.1080/17582024.2025.2607678](https://doi.org/10.1080/17582024.2025.2607678)
*PMID:*: 41446963
*Key Findings:*:
    - 9 RCTs, n=601: amantadine did not reduce fatigue vs placebo (SMD -0.22, p=0.37) and increased insomnia (OR 2.33).
*Conclusion:* The best human test of a catecholamine release enhancer for fatigue is negative — it argues against assuming a release-enhancer will work in ME/CFS.
*Limitations:* Multiple sclerosis, not ME/CFS; heterogeneous doses.
*Certainty Assessment:* 0.75 raw x 0.50 (other disease model) = *discounted 0.38*

17 Braley et al. 2024 — COMBO-MS (modafinil vs CBT)

*Full Citation:*: Braley TJ, Ehde DM, Alschuler KN, Little R, et al. Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm trial. *The Lancet Neurology*. 2024;23(11):1108-1118. [@Braley2024COMBOmodafinilMS]
*DOI:*: [10.1016/S1474-4422(24)00354-5](https://doi.org/10.1016/S1474-4422(24)00354-5)
*PMID:*: 39424559
*Key Findings:*:
    - n=336: modafinil and CBT gave similar fatigue reductions; combining them added no benefit; insomnia/anxiety were common on modafinil.
*Conclusion:* Modafinil's fatigue effect is modest and not additive to behavioural treatment — sets expectations for wake-promoters in ME/CFS.
*Limitations:* Multiple sclerosis; 12-week horizon.
*Certainty Assessment:* 0.80 raw x 0.50 (other disease model) = *discounted 0.40*

18 Palma and Kaufmann 2020 — Management of Orthostatic Hypotension

*Full Citation:*: Palma JA, Kaufmann H. Management of Orthostatic Hypotension. *Continuum (Minneapolis, Minn.)*. 2020;26(1):154-177. [@Palma2020OHmanagement]
*DOI:*: [10.1212/CON.0000000000000816](https://doi.org/10.1212/CON.0000000000000816)
*PMID:*: 31996627
*Key Findings:*:
    - Midodrine and droxidopa are first-line; atomoxetine is an off-label option; fludrocortisone has concerning long-term effects.
*Conclusion:* Frames the orthostatic-intolerance medication options relevant to ME/CFS+POTS.
*Limitations:* Review; neurogenic OH, not ME/CFS.
*Certainty Assessment:* 0.70 raw x 0.75 (general population) = *discounted 0.53*

19 Park et al. 2020 — Pharmacologic Treatment of Orthostatic Hypotension

*Full Citation:*: Park JW, Okamoto LE, Shibao CA, Biaggioni I. Pharmacologic treatment of orthostatic hypotension. *Autonomic Neuroscience*. 2020;229:102721. [@Park2020OHpharmacologic]
*DOI:*: [10.1016/j.autneu.2020.102721](https://doi.org/10.1016/j.autneu.2020.102721)
*PMID:*: 32979782
*Key Findings:*:
    - Peripheral sympathetic denervation responds to NE precursors/agonists (droxidopa, midodrine); central autonomic failure responds to NE enhancers (atomoxetine, pyridostigmine, yohimbine).
*Conclusion:* Supplies a mechanistic differential — drug response can localise the autonomic lesion; the basis for `@spec-peripheral-vs-central-autonomic-fork`.
*Limitations:* Review; OH populations.
*Certainty Assessment:* 0.70 raw x 0.75 (general population) = *discounted 0.53*

20 Schweitzer et al. 2023 — MARIPOSA (aroxybutynin + atomoxetine)

*Full Citation:*: Schweitzer PK, Taranto-Montemurro L, Ojile JM, Thein SG, et al. The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial. *American Journal of Respiratory and Critical Care Medicine*. 2023;208(12):1316-1327. [@Schweitzer2023MARIPOSA]
*DOI:*: [10.1164/rccm.202306-1036OC](https://doi.org/10.1164/rccm.202306-1036OC)
*PMID:*: 37812772
*Key Findings:*:
    - Phase II RCT, n=211: the combination improved the apnea-hypopnea index and fatigue, but atomoxetine alone reduced total sleep time.
*Conclusion:* Atomoxetine's isolated sleep-time reduction is a caution for sleep-fragile ME/CFS patients.
*Limitations:* Obstructive sleep apnea; industry-supported.
*Certainty Assessment:* 0.70 raw x 0.75 (general population) = *discounted 0.53*

21 Grossman et al. 1993 — Oral Yohimbine, BP, and Norepinephrine

*Full Citation:*: Grossman E, Rosenthal T, Peleg E, Holmes C, Goldstein DS. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. *Journal of Cardiovascular Pharmacology*. 1993;22(1):22-26. [@Grossman1993YohimbineNE]
*DOI:*: [10.1097/00005344-199307000-00004](https://doi.org/10.1097/00005344-199307000-00004)
*PMID:*: 7690091
*Key Findings:*:
    - Oral yohimbine raised mean blood pressure ~5 mmHg and plasma norepinephrine ~66%.
*Conclusion:* Safety basis for caution on α2-antagonist strategies in the hyperadrenergic/POTS population.
*Limitations:* Hypertensive subjects; small n.
*Certainty Assessment:* 0.65 raw x 0.75 (general population) = *discounted 0.49*

22 Bu et al. 2025 — Norepinephrine-ADRB2 Suppresses Microglia

*Full Citation:*: Bu S, Mou B, Xiang Z, Zhang L, et al. Hyperglycemia impairs microglia responding to retinal vasculopathy via enhanced norepinephrine-ADRB2 signaling. *Journal of Neuroinflammation*. 2025;23(1):14. [@Bu2025NeuroMicrogliaNE]
*DOI:*: [10.1186/s12974-025-03647-5](https://doi.org/10.1186/s12974-025-03647-5)
*PMID:*: 41361454
*Key Findings:*:
    - Mouse: norepinephrine acting on microglial β2-adrenergic receptors (ADRB2) suppressed microglial engagement.
*Conclusion:* One direction of the contested NE-microglia question: NE suppresses microglial activity.
*Limitations:* Mouse, retina; not ME/CFS.
*Certainty Assessment:* 0.55 raw x 0.50 (animal) = *discounted 0.28*

23 Evans et al. 2024 — Noradrenergic Inhibition and Neuroinflammation (opposite direction)

*Full Citation:*: Evans AK, Park HH, Woods CE, Lam RK, et al. Impact of noradrenergic inhibition on neuroinflammation and pathophysiology in mouse models of Alzheimer's disease. *Journal of Neuroinflammation*. 2024;21(1):322. [@Evans2024LocusCoeruleusMicroglia]
*DOI:*: [10.1186/s12974-024-03306-1](https://doi.org/10.1186/s12974-024-03306-1)
*PMID:*: 39696597
*Key Findings:*:
    - Mouse: inhibiting locus-coeruleus adrenergic signalling or β-adrenergic receptors potentiated neuroinflammation; microglial adrb2 deletion attenuated inflammation in females only.
*Conclusion:* Opposite to Bu 2025 — β2 signalling pro-inflammatory here, sex-specific. Establishes the NE-microglia direction as unresolved.
*Limitations:* Mouse AD model; sex-specific; not ME/CFS.
*Certainty Assessment:* 0.55 raw x 0.50 (animal) = *discounted 0.28*

24 Nedergaard 2026 — Oscillatory Sleep and Clearance

*Full Citation:*: Nedergaard M. The oscillatory biology of sleep: Linkage to dementia. *Science*. 2026;392(6800):821-826. [@Nedergaard2026OscillatorySleep]
*DOI:*: [10.1126/science.aeg2276](https://doi.org/10.1126/science.aeg2276)
*PMID:*: 42166599
*Key Findings:*:
    - Neuromodulators (norepinephrine, acetylcholine, serotonin, dopamine) are vasoactive and drive slow vasomotion (~50 s), the mechanical force for glymphatic clearance.
*Conclusion:* Supports the clearance arm of the loop and the arousal-and-clearance reframing.
*Limitations:* Review; not ME/CFS.
*Certainty Assessment:* 0.65 raw x 0.75 (general) = *discounted 0.49*

25 Hilz 2022 — taVNS Activates the LC-NE System

*Full Citation:*: Hilz MJ. Transcutaneous vagus nerve stimulation - A brief introduction and overview. *Autonomic Neuroscience*. 2022;243:103038. [@Hilz2022taVNS]
*DOI:*: [10.1016/j.autneu.2022.103038](https://doi.org/10.1016/j.autneu.2022.103038)
*PMID:*: 36201901
*Key Findings:*:
    - tVNS impulses reach the nucleus of the solitary tract and activate the locus-coeruleus-norepinephrine system.
*Conclusion:* Basis for taVNS as a non-pharmacological NE modulator (P3).
*Limitations:* Review.
*Certainty Assessment:* 0.60 raw x 0.75 (general) = *discounted 0.45*

26 Lv et al. 2024 — taVNS Acts via LC TH+ Neurons

*Full Citation:*: Lv H, Yu X, Wang P, Luo M, et al. Locus coeruleus tyrosine hydroxylase positive neurons mediated the peripheral and central therapeutic effects of transcutaneous auricular vagus nerve stimulation. *Brain Stimulation*. 2024;17(1):49-64. [@Lv2024taVNSLC]
*DOI:*: [10.1016/j.brs.2023.12.008](https://doi.org/10.1016/j.brs.2023.12.008)
*PMID:*: 38145753
*Key Findings:*:
    - Mouse: taVNS activated tyrosine-hydroxylase-positive neurons in the locus coeruleus, which mediated the therapeutic effects.
*Conclusion:* Direct evidence taVNS engages LC-NE neurons.
*Limitations:* Mouse; disease model.
*Certainty Assessment:* 0.55 raw x 0.50 (animal) = *discounted 0.28*

27 Killeen et al. 2013 — NE and Astrocytic Lactate Supply

*Full Citation:*: Killeen PR, Russell VA, Sergeant JA. A behavioral neuroenergetics theory of ADHD. *Neuroscience and Biobehavioral Reviews*. 2013;37(4):625-657. [@Killeen2013neLactate]
*DOI:*: [10.1016/j.neubiorev.2013.02.011](https://doi.org/10.1016/j.neubiorev.2013.02.011)
*PMID:*: 23454637
*Key Findings:*:
    - Increasing norepinephrine activates glial adrenoceptors and increases astrocytic lactate release to fuel neurons.
*Conclusion:* NE controls neuronal fuel *supply* — the correct direction for the NE-lactate link (P4).
*Limitations:* Theoretical review.
*Certainty Assessment:* 0.50 raw x 0.75 (general) = *discounted 0.38*

28 Hertz et al. 2015 — Noradrenaline Stimulates Astrocytic Glycogenolysis

*Full Citation:*: Hertz L, Xu J, Song D, Du T, et al. Astrocytic glycogenolysis: mechanisms and functions. *Metabolic Brain Disease*. 2015;30(1):317-333. [@Hertz2015neGlycogenolysis]
*DOI:*: [10.1007/s11011-014-9536-1](https://doi.org/10.1007/s11011-014-9536-1)
*PMID:*: 24744118
*Key Findings:*:
    - Noradrenaline and β-adrenergic agonists stimulate astrocytic glycogenolysis, supplying lactate.
*Conclusion:* Mechanistic arm linking low NE to impaired neuronal fuel delivery.
*Limitations:* Review.
*Certainty Assessment:* 0.55 raw x 0.75 (general) = *discounted 0.41*

29 Arnsten and Shanafelt 2021 — Arousal Inverted-U and Prefrontal Function

*Full Citation:*: Arnsten AFT, Shanafelt T. Physician Distress and Burnout: The Neurobiological Perspective. *Mayo Clinic Proceedings*. 2021;96(3):763-769. [@Arnsten2021ArousalPFC]
*DOI:*: [10.1016/j.mayocp.2020.12.027](https://doi.org/10.1016/j.mayocp.2020.12.027)
*PMID:*: 33673923
*Key Findings:*:
    - Prefrontal function is impaired when arousal modulators (norepinephrine, dopamine, acetylcholine) are inadequate OR excessive — the inverted-U.
*Conclusion:* Supports the arousal arm of the reframing, with a ceiling as well as a floor.
*Limitations:* Review.
*Certainty Assessment:* 0.60 raw x 0.75 (general) = *discounted 0.45*

30 Tsigos and Chrousos 2002 — LC/NE Arousal and Chronic Fatigue

*Full Citation:*: Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. *Journal of Psychosomatic Research*. 2002;53(4):865-871. [@Tsigos2002stressLC]
*DOI:*: [10.1016/s0022-3999(02)00429-4](https://doi.org/10.1016/s0022-3999(02)00429-4)
*PMID:*: 12377295
*Key Findings:*:
    - The CRH and LC/NE systems stimulate arousal and attention; low HPA-axis and LC/NE activity is noted in chronic fatigue and fibromyalgia.
*Conclusion:* Early framing of fatigue as low LC/NE arousal.
*Limitations:* Review.
*Certainty Assessment:* 0.55 raw x 0.75 (general) = *discounted 0.41*

31 Kang and Banaji 2020

*Full Citation:*: Kang O, Banaji MR. Pupillometric decoding of high-level musical imagery. *Consciousness and Cognition*. 2020;77:102862. [@Kang2020Pupillometry]
*DOI:*: [10.1016/j.concog.2019.102862](https://doi.org/10.1016/j.concog.2019.102862)
*PMID:*: 31863916
*Key Findings:*:
    - Human: pupils dilate/constrict with noradrenergic activity, independent of light.
*Certainty Assessment:* 0.55 raw x 0.75 = 0.41

32 O’Callaghan et al. 2025

*Full Citation:*: O'Callaghan C, Hezemans FH, Subramaniam N, et al. Pharmacological and pupillary evidence for the noradrenergic contribution to reinforcement learning in Parkinson's disease. *Communications Biology*. 2025;8(1):1223. [@OCallaghan2025PupillaryNE]
*DOI:*: [10.1038/s42003-025-08627-2](https://doi.org/10.1038/s42003-025-08627-2)
*PMID:*: 40813904
*Key Findings:*:
    - Human RCT: atomoxetine increased baseline pupil diameter, correlated with improvement.
*Certainty Assessment:* 0.65 raw x 0.75 = 0.49

33 Barcomb et al. 2022

*Full Citation:*: Barcomb K, Olah SS, Kennedy MJ, et al. Properties and modulation of excitatory inputs to the locus coeruleus. *The Journal of Physiology*. 2022;600(22):4897-4916. [@Barcomb2022LCexcitatoryInputs]
*DOI:*: [10.1113/JP283605](https://doi.org/10.1113/JP283605)
*PMID:*: 36156249
*Key Findings:*:
    - Mouse: orexin had minimal effect on LC excitatory inputs.
*Certainty Assessment:* 0.60 raw x 0.50 = 0.30

34 Zhou et al. 2023

*Full Citation:*: Zhou C, Wang L, Cheng W, et al. Two distinct trajectories of clinical and neurodegeneration events in Parkinson's disease. *NPJ Parkinson's Disease*. 2023;9(1):111. [@Zhou2023PDtrajectories]
*DOI:*: [10.1038/s41531-023-00556-3](https://doi.org/10.1038/s41531-023-00556-3)
*PMID:*: 37443179
*Key Findings:*:
    - Human imaging: a subtype shows early SN and LC degeneration.
*Certainty Assessment:* 0.65 raw x 0.50 = 0.33

35 Aston-Jones and Cohen 2005

*Full Citation:*: Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. *Annual Review of Neuroscience*. 2005;28:403-450. [@AstonJones2005AdaptiveGain]
*DOI:*: [10.1146/annurev.neuro.28.061604.135709](https://doi.org/10.1146/annurev.neuro.28.061604.135709)
*PMID:*: 16022602
*Key Findings:*:
    - Theory: LC phasic/tonic modes; adaptive gain.
*Certainty Assessment:* 0.70 raw x 0.75 = 0.53

36 Medina-Coss Y Leon et al. 2025

*Full Citation:*: Medina-Coss Y Leon R, Lezama E, Marquez I, et al. Adrenergic Modulation of Cortical Gain and Sensory Processing in the Mouse Visual Cortex. *Brain Sciences*. 2025;15(4). [@MedinaCoss2025CorticalGain]
*DOI:*: [10.3390/brainsci15040406](https://doi.org/10.3390/brainsci15040406)
*PMID:*: 40309887
*Key Findings:*:
    - Mouse: NE modulates cortical E/I and signal-to-noise; atomoxetine flattened SNR.
*Certainty Assessment:* 0.55 raw x 0.50 = 0.28

37 Lo et al. 2022

*Full Citation:*: Lo Y, Yi PL, Hsiao YT, et al. Hypocretin in locus coeruleus and dorsal raphe nucleus mediates inescapable footshock stimulation (IFS)-induced REM sleep alteration. *Sleep*. 2022;45(3). [@Lo2022HypocretinLC]
*DOI:*: [10.1093/sleep/zsab301](https://doi.org/10.1093/sleep/zsab301)
*PMID:*: 34969120
*Key Findings:*:
    - Rodent: hypocretin in LC mediates stress REM disruption.
*Certainty Assessment:* 0.55 raw x 0.50 = 0.28

38 Del Campo et al. 2011

*Full Citation:*: Del Campo N, Chamberlain SR, Sahakian BJ, et al. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. *Biological Psychiatry*. 2011;69(12):e145-e157. [@DelCampo2011DANEinADHD]
*DOI:*: [10.1016/j.biopsych.2011.02.036](https://doi.org/10.1016/j.biopsych.2011.02.036)
*PMID:*: 21550021
*Key Findings:*:
    - Review: DA/NA modulate fronto-striato-cerebellar executive circuits.
*Certainty Assessment:* 0.65 raw x 0.75 = 0.49

39 Gao et al. 2019

*Full Citation:*: Gao J, Xi B, Chen K, et al. The stress hormone norepinephrine increases the growth and virulence of Aeromonas hydrophila. *MicrobiologyOpen*. 2019;8(4):e00664. [@Gao2019NEAeromonas]
*DOI:*: [10.1002/mbo3.664](https://doi.org/10.1002/mbo3.664)
*PMID:*: 29897673
*Key Findings:*:
    - NE increased bacterial growth and virulence.
*Certainty Assessment:* 0.60 raw x 0.40 = 0.24

40 Dicks 2022

*Full Citation:*: Dicks LMT. Gut Bacteria and Neurotransmitters. *Microorganisms*. 2022;10(9). [@Dicks2022GutBacteriaNeurotransmitters]
*DOI:*: [10.3390/microorganisms10091838](https://doi.org/10.3390/microorganisms10091838)
*PMID:*: 36144440
*Key Findings:*:
    - Review: gut bacteria produce/consume neurotransmitters incl. NE.
*Certainty Assessment:* 0.55 raw x 0.50 = 0.28

41 Matsuyama et al. 2021

*Full Citation:*: Matsuyama S, Tanaka Y, Hasebe R, et al. Gateway Reflex and Mechanotransduction. *Frontiers in Immunology*. 2021;12:780451. [@Matsuyama2021GatewayReflex]
*DOI:*: [10.3389/fimmu.2021.780451](https://doi.org/10.3389/fimmu.2021.780451)
*PMID:*: 35003096
*Key Findings:*:
    - NE reduces tight junctions and permits T-cell entry at specific vessels.
*Certainty Assessment:* 0.55 raw x 0.75 = 0.41

42 MCAS-Stack Drug Mechanisms (mcas-stack-drug-mechanisms) — added 2026-09-29

43 Gibbs et al. 2012 — H4 Receptors in Mast Cells and Basophils (A1)

Full Citation:: Gibbs BF, Levi-Schaffer F. H4 receptors in mast cells and basophils: a new therapeutic target for allergy? Frontiers in Bioscience (Landmark Edition). 2012;17(2):430–437. (Gibbs and Levi-Schaffer 2012)
DOI:: 10.2741/3936
PMID:: 22201753
Key Findings:: - Itch and other histamine functions are controlled by H4R, not H1R - H4R expressed on mast-cell precursors, mature basophils, and eosinophils (chemotaxis/trafficking) - Combined H1+H4 antagonism proposed
Conclusion:: H4R covers histamine functions H1 blockade does not reach.
Limitations:: Review; no original data.
Certainty:: Raw 0.60; population general; discounted 0.45.

44 Cowden et al. 2010 — H4 Receptor Mediates Inflammation and Pruritus (A1)

Full Citation:: Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. Journal of Investigative Dermatology. 2010;130(4):1023–1033. (Cowden et al. 2010)
DOI:: 10.1038/jid.2009.358
PMID:: 19907432
Key Findings:: - Two H4R antagonists reduced oedema, mast-cell and eosinophil infiltration in Th2 skin model - H4R antagonism reduced IL-4, IL-5, IL-17 and inhibited pruritus
Conclusion:: H4R mediates pruritus and Th2 inflammation distinct from H1.
Limitations:: Mouse model.
Certainty:: Raw 0.65; population animal; discounted 0.33.

45 Ohsawa and Hirasawa 2014 — H1 and H4 Receptors in Atopic Dermatitis (A1)

Full Citation:: Ohsawa Y, Hirasawa N. The role of histamine H1 and H4 receptors in atopic dermatitis: from basic research to clinical study. Allergology International. 2014;63(4):533–542. (Ohsawa and Hirasawa 2014)
DOI:: 10.2332/allergolint.13-RA-0675
PMID:: 25249063
Key Findings:: - H4R on eosinophils, mast cells, basophils, Th2 cells, and sensory neurons - Combined H1R+H4R blockade inhibited itch and chronic allergic inflammation with efficacy comparable to prednisolone - JNJ39758979 (H4R antagonist) markedly anti-pruritic in phase II AD
Conclusion:: H1+H4 dual blockade is more effective than H1 alone.
Limitations:: Review; H4R antagonists not approved.
Certainty:: Raw 0.60; population general; discounted 0.45.

46 Walter et al. 2011 — Histamine H4 Receptor: Targeting Inflammatory Disorders (A1)

Full Citation:: Walter M, Kottke T, Stark H. The histamine H4 receptor: targeting inflammatory disorders. European Journal of Pharmacology. 2011;668(1-2):1–5. (Walter, Kottke, and Stark 2011)
DOI:: 10.1016/j.ejphar.2011.06.029
PMID:: 21741967
Key Findings:: - H4R on immune cells mediates chemotaxis - H1 antagonists unsatisfying in chronic pruritus/asthma/allergic rhinitis - H1+H4 synergism proposed; first H4 antagonists reached clinical phase
Conclusion:: H4R is a distinct, therapeutically relevant gap in the antihistamine stack.
Limitations:: Review.
Certainty:: Raw 0.55; population general; discounted 0.41.

47 Jin et al. 2024 — Izuforant H4R Inhibitor Phase I (A1)

Full Citation:: Jin BH, Hong T, Yoo BW, et al. Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: a phase I single and multiple ascending dose study. Clinical and Translational Science. 2024;17(10):e70032. (Jin et al. 2024)
DOI:: 10.1111/cts.70032
PMID:: 39432406
Key Findings:: - Phase I SAD/MAD of selective H4R antagonist izuforant in 64 healthy volunteers - PK/PD/safety characterised; no approved H4R antagonist yet
Conclusion:: H4R blockade remains at clinical-development stage.
Limitations:: Healthy subjects only; no efficacy data.
Certainty:: Raw 0.55; population general; discounted 0.41.

48 Mehta et al. 2020 — Enigmatic Histamine Receptor H4 (A1)

Full Citation:: Mehta P, Miszta P, Rzodkiewicz P, et al. Enigmatic histamine receptor H4 for potential treatment of multiple inflammatory, autoimmune, and related diseases. Life. 2020;10(4):50. (Mehta et al. 2020)
DOI:: 10.3390/life10040050
PMID:: 32344736
Key Findings:: - H4R activation mediates mast-cell activation and eosinophil chemotaxis - H4R ligands studied across inflammation, allergy, autoimmunity, neuropathic pain
Conclusion:: H4R is an unaddressed target relevant to mast-cell and neuroimmune disease.
Limitations:: Review.
Certainty:: Raw 0.55; population general; discounted 0.41.

49 Ocak et al. 2020 — Tryptase Inhibition Attenuates Neuroinflammation via PAR-2 (A2)

Full Citation:: Ocak U, Eser Ocak P, Huang L, et al. Inhibition of mast cell tryptase attenuates neuroinflammation via PAR-2/p38/NF-kB pathway following asphyxial cardiac arrest in rats. Journal of Neuroinflammation. 2020;17(1):144. (Ocak et al. 2020)
DOI:: 10.1186/s12974-020-01808-2
PMID:: 32366312
Key Findings:: - Tryptase acts via PAR-2/p38/NF-kB, independent of histamine receptors - Tryptase inhibition attenuated neuroinflammation
Conclusion:: Tryptase is a mast-cell mediator that H1/H2/CysLT1 blockade cannot neutralise (mediator escape).
Limitations:: Rat model; cardiac-arrest context.
Certainty:: Raw 0.55; population animal; discounted 0.28.

50 Qin et al. 2021 — Mast Cells Aggravate Injury via Microglial PAR-2 (A2)

Full Citation:: Qin B, Peng Y, Zhong C, et al. Mast cells mediate inflammatory injury and aggravate neurological impairment in experimental subarachnoid hemorrhage through microglial PAR-2 pathway. Frontiers in Cellular Neuroscience. 2021;15:710481. (Qin et al. 2021)
DOI:: 10.3389/fncel.2021.710481
PMID:: 34646122
Key Findings:: - Mast cells aggravate neurological injury via microglial PAR-2 (tryptase receptor) - Links mast-cell tryptase directly to microglial activation
Conclusion:: Supports the tryptase→PAR2→microglia arm of mediator escape.
Limitations:: Rat model.
Certainty:: Raw 0.55; population animal; discounted 0.28.

51 Lakatos and Rosta 2025 — Bidirectional Microglia–Mast Cell Interplay (A2)

Full Citation:: Lakatos S, Rosta J. Bidirectional interplay between microglia and mast cells. International Journal of Molecular Sciences. 2025;26(15):7556. (Lakatos and Rosta 2025)
DOI:: 10.3390/ijms26157556
PMID:: 40806683
Key Findings:: - Reviews mast-cell/microglia signalling in neuroinflammation and chronic pain - Includes tryptase/PAR-2 and other non-histaminergic routes
Conclusion:: Non-histaminergic mast-cell→microglia signalling exists and bypasses antihistamines.
Limitations:: Review.
Certainty:: Raw 0.55; population general; discounted 0.41.

52 Kupczyk and Kuna 2017 — PGD2/CRTH2/DP1 Pathway (A2)

Full Citation:: Kupczyk M, Kuna P. Targeting the PGD2/CRTH2/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives. Drugs. 2017;77(12):1281–1294. (Kupczyk and Kuna 2017)
DOI:: 10.1007/s40265-017-0777-2
PMID:: 28612233
Key Findings:: - PGD2 from degranulating mast cells acts via DP1, CRTH2 (DP2), TP receptors — none blocked by H1/H2 antihistamines or CysLT1 antagonists - CRTH2 drives Th2, eosinophil and basophil migration/activation
Conclusion:: PGD2 is a pharmacologically distinct mediator-escape route.
Limitations:: Review; CRTH2 antagonists not widely approved.
Certainty:: Raw 0.60; population general; discounted 0.45.

53 Maintz and Novak 2007 — Histamine and Histamine Intolerance (A3)

Full Citation:: Maintz L, Novak N. Histamine and histamine intolerance. American Journal of Clinical Nutrition. 2007;85(5):1185–1196. (Maintz and Novak 2007)
DOI:: 10.1093/ajcn/85.5.1185
PMID:: 17490952
Key Findings:: - DAO is the main enzyme for ingested/extracellular histamine; HNMT is cytosolic (intracellular only) - Reduced DAO activity drives symptoms mimicking allergy - Symptoms respond to histamine-restricted diet or antihistamines
Conclusion:: Clearance-side (DAO/HNMT) and receptor-side (H1/H2) are complementary arms of histamine management.
Limitations:: Review; few double-blind provocation studies.
Certainty:: Raw 0.65; population general; discounted 0.49.

54 Rentzos et al. 2024 — DAO Measurement in Histamine Intolerance (A3)

Full Citation:: Rentzos G, Weisheit A, Ekerljung L, van Odijk J. Measurement of diamine oxidase (DAO) during low-histamine or ordinary diet in patients with histamine intolerance. European Journal of Clinical Nutrition. 2024;78(8):726–731. (Rentzos et al. 2024)
DOI:: 10.1038/s41430-024-01448-2
PMID:: 38769188
Key Findings:: - Serum DAO did not reliably distinguish histamine-intolerance patients or track diet response - Questions serum DAO as a diagnostic biomarker
Conclusion:: DAO clearance is real, but serum DAO measurement is an unreliable diagnostic.
Limitations:: Small clinical study; serum vs tissue DAO mismatch.
Certainty:: Raw 0.55; population general; discounted 0.41.

55 Zybul et al. 2026 — Diamine Oxidase and Gastrointestinal Diseases (A3)

Full Citation:: Zybul P, Przybylkowski A, Wojas O, Samolinski B. Diamine oxidase and gastrointestinal diseases. Biomolecules. 2026;16(8):1136. (Zybul et al. 2026)
DOI:: 10.3390/biom16081136
PMID:: 42650803
Key Findings:: - Reviews DAO in gastrointestinal disease and histamine intolerance - Covers DAO activity measurement, AOC1 gene, dietary/supplemental DAO
Conclusion:: Updates the clearance-side management of histamine.
Limitations:: Review.
Certainty:: Raw 0.55; population general; discounted 0.41.

56 Protasio Netto et al. 2026 — Histamine Intolerance as Fibromyalgia Subtype (A3)

Full Citation:: Protasio Netto J, Lana JF, Parma A, et al. Is histamine intolerance a treatable subtype of fibromyalgia? Evidence and clinical implications — narrative review. Frontiers in Pain Research. 2026;7:1786437. (Protasio Netto et al. 2026)
DOI:: 10.3389/fpain.2026.1786437
PMID:: 42146886
Key Findings:: - Proposes histamine intolerance (DAO deficiency) as a potentially treatable fibromyalgia subtype - Relevant to ME/CFS-adjacent FM population
Conclusion:: DAO deficiency may define a treatable subgroup in FM; untested in ME/CFS.
Limitations:: Narrative review; no controlled trials.
Certainty:: Raw 0.45; population fibromyalgia; discounted 0.36.

57 Kadiyska et al. 2025 — AOC1 and HNMT Variants in ASD (A3)

Full Citation:: Kadiyska T, Tourtourikov I, Madzharova D, et al. Impact of AOC1 and HNMT variants on the therapeutic outcomes of a histamine reducing diet in autism spectrum disorder. Journal of Molecular Neuroscience. 2025;75(3):105. (Kadiyska et al. 2025)
DOI:: 10.1007/s12031-025-02399-4
PMID:: 40794387
Key Findings:: - AOC1 (DAO) and HNMT variants associated with differential response to a histamine-reducing diet - HNMT-specific literature otherwise dominated by CNS disorders, not histamine intolerance
Conclusion:: HNMT variation modifies histamine-clearance outcomes; HNMT/HIT link remains understudied.
Limitations:: ASD cohort; associative.
Certainty:: Raw 0.45; population general; discounted 0.34.

58 Hu Frisk et al. 2017 — Copper Regulates MITF:Tryptase Axis in Mast Cells (B1)

Full Citation:: Hu Frisk JM, Kjellen L, Kaler SG, Pejler G, Ohrvik H. Copper regulates maturation and expression of an MITF:tryptase axis in mast cells. Journal of Immunology. 2017;199(12):4132–4141. (Hu Frisk et al. 2017)
DOI:: 10.4049/jimmunol.1700786
PMID:: 29127151
Key Findings:: - Copper regulates an MITF:tryptase axis: copper overload decreased tryptase, starvation increased it - Copper status did NOT alter histamine storage or IgE-mediated degranulation
Conclusion:: Copper’s mast-cell link is via tryptase, not histamine — refines the simple copper→DAO→histamine model.
Limitations:: In vitro mast cells.
Certainty:: Raw 0.60; population in vitro; discounted 0.24.

59 Schuschke et al. 1994 — Copper Deficiency Increases Mast Cell Population (B1)

Full Citation:: Schuschke DA, Saari JT, West CA, Miller FN. Dietary copper deficiency increases the mast cell population of the rat. Proceedings of the Society for Experimental Biology and Medicine. 1994;207(3):274–277. (Schuschke et al. 1994)
DOI:: 10.3181/00379727-207-43816
PMID:: 7528379
Key Findings:: - Copper deficiency increased mast-cell numbers (78 vs 51 cells/section) - No change in per-cell histamine content or degranulation sensitivity
Conclusion:: Copper status links to mast-cell density, not histamine content.
Limitations:: Rat model; dated.
Certainty:: Raw 0.50; population animal; discounted 0.25.

60 Murakawa et al. 2025 — Copper Amine Oxidase Catalysis (B1)

Full Citation:: Murakawa T, Suzuki M, Fukui K, et al. Real-time capture of domain movements during copper amine oxidase catalysis by mix-and-inject serial crystallography. Nature Communications. 2025;16(1):11149. (Murakawa et al. 2025)
DOI:: 10.1038/s41467-025-67230-5
PMID:: 41413268
Key Findings:: - Structural confirmation of the copper-dependent catalytic mechanism of copper amine oxidase (DAO class)
Conclusion:: Provides the biochemical anchor that DAO activity requires copper.
Limitations:: Structural/in vitro; no clinical translation.
Certainty:: Raw 0.55; population in vitro; discounted 0.22.

61 Jutel et al. 2001 — Histamine Regulates T-Cell Responses via H1/H2 (B2)

Full Citation:: Jutel M, Watanabe T, Klunker S, et al. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature. 2001;413(6854):420–425. (Jutel et al. 2001)
DOI:: 10.1038/35096564
PMID:: 11574888
Key Findings:: - Histamine enhances Th1 via H1R; negatively regulates both Th1 and Th2 via H2R - H1R-knockout: suppressed IFN-gamma, Th2 shift; H2R-knockout: both up
Conclusion:: Provides the receptor basis for H1-blockade redistributing histamine to H2 and the resulting immune-polarisation consequences.
Limitations:: Mostly mouse knockout; human in vitro.
Certainty:: Raw 0.70; population animal + in vitro; discounted 0.35.

62 Elenkov et al. 1998 — Histamine Suppresses IL-12, Stimulates IL-10 via H2 (B2)

Full Citation:: Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. Journal of Immunology. 1998;161(5):2586–2593. (Elenkov et al. 1998)
PMID:: 9725260
Key Findings:: - Histamine suppresses IL-12 and stimulates IL-10 in human monocytes via H2R - Th1-suppressive, Th2/anti-inflammatory signature
Conclusion:: Mechanistic basis for H2-mediated immune suppression under histamine redistribution.
Limitations:: In vitro human cells.
Certainty:: Raw 0.55; population in vitro; discounted 0.22.

63 Jutel et al. 2009 — Histamine, Histamine Receptors and Immune Pathology (B2)

Full Citation:: Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. Clinical and Experimental Allergy. 2009;39(12):1786–1800. (Jutel, Akdis, and Akdis 2009)
DOI:: 10.1111/j.1365-2222.2009.03374.x
PMID:: 20085595
Key Findings:: - Reviews the four histamine receptors in immune regulation - H1 vs H2 differential effects on T-cell polarisation; H4 in chemotaxis
Conclusion:: Consolidates the receptor-differential model of histamine immunomodulation.
Limitations:: Review.
Certainty:: Raw 0.60; population general; discounted 0.45.

64 Packard and Khan 2003 — Histamine Effects on Th1/Th2 Balance (B2)

Full Citation:: Packard KA, Khan MM. Effects of histamine on Th1/Th2 cytokine balance. International Immunopharmacology. 2003;3(7):909–920. (Packard and Khan 2003)
DOI:: 10.1016/S1567-5769(02)00235-7
PMID:: 12810348
Key Findings:: - Reviews receptor-specific (H1 vs H2) and dose-dependent histamine effects on Th1/Th2 cytokines
Conclusion:: Supports the Th1/Th2 arm of the redistribution hypothesis.
Limitations:: Review.
Certainty:: Raw 0.50; population general; discounted 0.38.

65 Bissonnette 1996 — Histamine Inhibits Mast-Cell TNF-alpha via H2/H3 (B3)

Full Citation:: Bissonnette EY. Histamine inhibits tumor necrosis factor alpha release by mast cells through H2 and H3 receptors. American Journal of Respiratory Cell and Molecular Biology. 1996;14(6):620–626. (Bissonnette 1996)
DOI:: 10.1165/ajrcmb.14.6.8652190
PMID:: 8652190
Key Findings:: - Histamine inhibits TNF-alpha release from mast cells via H2 and H3 receptors - Partially mediated by PGE2
Conclusion:: Direct evidence for autocrine negative feedback of histamine on mast-cell mediator release via H2/H3.
Limitations:: Rat peritoneal mast cells; dated; single study.
Certainty:: Raw 0.45; population animal (in vitro); discounted 0.23.

66 Alstadhaug 2014 — Histamine in Migraine and Brain (B3)

Full Citation:: Alstadhaug KB. Histamine in migraine and brain. Headache. 2014;54(2):246–259. (Alstadhaug 2014)
DOI:: 10.1111/head.12293
PMID:: 24433203
Key Findings:: - Postulated negative feedback of histamine on mast-cell release via H3 autoreceptor - Most antihistamines ineffective as acute migraine therapy
Conclusion:: Secondary support for autocrine histamine feedback on mast cells (note: H3, not H2).
Limitations:: Review; mechanism postulated not proven.
Certainty:: Raw 0.45; population general; discounted 0.34.

67 Kutukova et al. 2025 — Dual Effects of Acetylcholine on Mast Cells (B4)

Full Citation:: Kutukova NA, Trulioff AS, Polevshchikov AV, Shamova OV. Dual effects of acetylcholine on mast cell-nerve interactions. Doklady Biological Sciences. 2025;525(1):350–353. (Kutukova et al. 2025)
DOI:: 10.1134/S001249662560054X
PMID:: 41329279
Key Findings:: - ACh activates resting mast cells via M3 muscarinic receptor - ACh suppresses degranulation in stimulated mast cells via a7 nicotinic receptor
Conclusion:: Cholinergic–mast-cell interaction is receptor-dependent and bidirectional.
Limitations:: HMC-1 cell line in vitro.
Certainty:: Raw 0.50; population in vitro; discounted 0.20.

68 Kilinc et al. 2024 — Cholinergic Modulation of Meningeal Mast Cells (B4)

Full Citation:: Kilinc E, Torun IE, Baranoglu Kilinc Y. Meningeal mast cell-mediated mechanisms of cholinergic system modulation in neurogenic inflammation underlying the pathophysiology of migraine. European Journal of Neuroscience. 2024;59(9):2181–2192. (Kilinc, Torun, and Baranoglu Kilinc 2024)
DOI:: 10.1111/ejn.15888
PMID:: 36485173
Key Findings:: - Neostigmine (cholinesterase inhibitor) augmented mast-cell degranulation, CGRP, C-fos (blocked by atropine) - Cromolyn (mast-cell stabiliser) reduced these
Conclusion:: Enhancing cholinergic tone increases mast-cell degranulation — directly relevant to pyridostigmine/mestinon.
Limitations:: Rat model.
Certainty:: Raw 0.55; population animal; discounted 0.28.

69 Mishra et al. 2010 — Nicotine Inhibits Mast-Cell Leukotrienes via a7 (B4)

Full Citation:: Mishra NC, Rir-sima-ah J, Boyd RT, et al. Nicotine inhibits Fc-epsilon-RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha7/alpha9/alpha10-nicotinic receptors. Journal of Immunology. 2010;185(1):588–596. (Mishra et al. 2010)
DOI:: 10.4049/jimmunol.0902227
PMID:: 20505147
Key Findings:: - Nicotine inhibits IgE-mediated cysteinyl leukotriene and cytokine production via a7/a9/a10 nicotinic receptors, without affecting degranulation
Conclusion:: a7-nAChR agonism selectively suppresses mast-cell mediator release (cholinergic negative-control arm).
Limitations:: In vitro.
Certainty:: Raw 0.50; population in vitro; discounted 0.20.

70 Woestemeier et al. 2026 — Vagal Signaling and Mesenteric Mast Cells (B4)

Full Citation:: Woestemeier A, Schwandt T, Lingohr P, et al. Mast cell activation within the mesentery depends on vagal signaling following abdominal surgery. Surgery Open Science. 2026;31:44–53. (Woestemeier et al. 2026)
DOI:: 10.1016/j.sopen.2026.03.005
PMID:: 41952969
Key Findings:: - Mesenteric mast-cell degranulation required intact vagal signalling (prevented by vagotomy) - In vitro degranulation triggered by substance P, nicotine, bethanechol
Conclusion:: Mast-cell activation is vagal/cholinergic-dependent in vivo.
Limitations:: Mouse model.
Certainty:: Raw 0.50; population animal; discounted 0.25.

71 Wang et al. 2017 — Nicotine Accelerates Atherosclerosis via a7 on Mast Cells (B4)

Full Citation:: Wang C, Chen H, Zhu W, et al. Nicotine accelerates atherosclerosis in apolipoprotein E-deficient mice by activating alpha7 nicotinic acetylcholine receptor on mast cells. Arteriosclerosis, Thrombosis, and Vascular Biology. 2017;37(1):53–65. (Wang et al. 2017)
DOI:: 10.1161/ATVBAHA.116.307264
PMID:: 27834689
Key Findings:: - Nicotine accelerates atherosclerosis via a7-nAChR on mast cells - HARM SIGNAL: a7-nAChR agonism on mast cells can be pro-inflammatory/pro-atherogenic
Conclusion:: Caution against cholinergic approaches that activate mast-cell a7 receptors.
Limitations:: Mouse model.
Certainty:: Raw 0.55; population animal; discounted 0.28.

72 Elsaghir et al. 2026 — New Autoantibodies in Sjögren’s Disease

*Full Citation:*: Elsaghir A, Witte T. New autoantibodies in Sjögren's disease. *Current Opinion in Immunology*. 2026;99:102722. [@Elsaghir2026SjogrenAutoAbs]
*DOI:*: [10.1016/j.coi.2025.102722](https://doi.org/10.1016/j.coi.2025.102722)
*PMID:*: 41534451
*Study Design:*: Narrative review
*Key Findings:*:
    - Anti-muscarinic M3 receptor (anti-M3R) autoantibodies show high diagnostic sensitivity and specificity for Ro/SS-A-negative Sjögren's disease
    - M3R is a component of a validated 5-marker panel (FNBP4, SNRPC, CCL4, M3R, KDM6B): 46% sensitivity, 95% specificity
    - Seronegative SjD diagnosis currently requires invasive salivary-gland biopsy, motivating non-invasive autoantibody biomarkers
*Conclusion:*: Anti-M3R is a bona fide diagnostic autoantibody in the Sjögren's terrain, supporting a functional M3-receptor-autoimmunity signal.
*Limitations:*: Review; no ME/CFS cohort; M3R panels still require large-cohort validation.
*Certainty:*: Raw 0.55 (review); population Sjögren's weight 0.75; discounted 0.41.

73 Abe et al. 2020 — M3-Receptor-Reactive Th17 Cells in Primary Sjögren’s Syndrome

*Full Citation:*: Abe S, Tsuboi H, Kudo H, et al.\ M3 muscarinic acetylcholine receptor-reactive Th17 cells in primary Sjögren's syndrome. *JCI Insight*. 2020;5(15):e135982. [@Abe2020M3RTh17Sjogren]
*DOI:*: [10.1172/jci.insight.135982](https://doi.org/10.1172/jci.insight.135982)
*PMID:*: 32614803
*Study Design:*: ELISpot + functional T-cell assay
*Sample Size:*: 10 primary SjD, 10 healthy, 5 IgG4-related disease
*Key Findings:*:
    - M3R-reactive IL-17-secreting Th17 cells detected in 5/10 pSS patients, 0/10 healthy, 0/5 IgG4-RD
    - Dominant T-cell epitope = M3R peptide 83-95, partly HLA-DR-restricted
    - M3R-reactive Th17 positivity correlated with higher anti-M3R antibody titers
*Conclusion:*: M3R is a tissue-specific autoantigen with both T-cell (Th17) and B-cell (antibody) arms, reinforcing its functional significance.
*Limitations:*: Small n; Sjögren's population, not ME/CFS.
*Certainty:*: Raw 0.50 (n=10, top journal); population weight 0.75; discounted 0.38.

74 Schiweck et al. 2026 — Systematic Review of POTS Treatment

*Full Citation:*: Schiweck N, Langer K, Maier A, Vilser D, Spiegler J. Systematic literature review: treatment of postural orthostatic tachycardia syndrome (POTS). *Clinical Autonomic Research*. 2026;36(1):3-16. [@Schiweck2026POTSTreatment]
*DOI:*: [10.1007/s10286-025-01172-2](https://doi.org/10.1007/s10286-025-01172-2)
*PMID:*: 41225175
*Study Design:*: Systematic literature review
*Sample Size:*: 45 of 3853 studies
*Key Findings:*:
    - Single studies suggest pyridostigmine and midodrine have beneficial hemodynamic effects in POTS
    - Ivabradine and beta-blockers show significant effects
    - Evidence base limited by small studies and absence of large randomized trials
*Conclusion:*: Pyridostigmine is a recognized but weakly-evidenced POTS therapy, supporting its use as an autonomic/perfusion probe rather than a first-line treatment.
*Limitations:*: No randomized pyridostigmine trial; POTS population.
*Certainty:*: Raw 0.70 (systematic review); population POTS weight 0.80; discounted 0.56.

75 Kwok et al. 2025 — Treatments for POTS: Systematic Review of Randomized Trials

*Full Citation:*: Kwok CS, Lee S, Hall M, et al.\ The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials. *Trends in Cardiovascular Medicine*. 2025;35(8):517-527. [@Kwok2025POTSRCTs]
*DOI:*: [10.1016/j.tcm.2025.07.001](https://doi.org/10.1016/j.tcm.2025.07.001)
*PMID:*: 40653179
*Study Design:*: Systematic review of randomized trials
*Key Findings:*:
    - Pyridostigmine is among the pharmacological agents evaluated for POTS
    - Limited randomized-trial evidence for most POTS pharmacotherapies
*Conclusion:*: Confirms the weak RCT base for pyridostigmine in POTS.
*Limitations:*: Heterogeneous trials; POTS population.
*Certainty:*: Raw 0.70; population weight 0.80; discounted 0.56.

76 Chung & Raj 2026 — POTS: A Review (JAMA)

*Full Citation:*: Chung TH, Raj SR. Postural Orthostatic Tachycardia Syndrome (POTS): A Review. *JAMA*. 2026. doi:10.1001/jama.2026.14809. [@Chung2026POTSReview]
*DOI:*: [10.1001/jama.2026.14809](https://doi.org/10.1001/jama.2026.14809)
*PMID:*: 42635998
*Study Design:*: Clinical review
*Key Findings:*:
    - Lists pyridostigmine among individualized pharmacological options for POTS
    - Symptoms include gastroparesis and cognitive dysfunction
    - Evidence for many interventions limited by small studies
*Conclusion:*: Pyridostigmine sits in the POTS pharmacopeia, supporting its use as a cholinergic/autonomic probe.
*Limitations:*: Review; no pyridostigmine-specific outcome data.
*Certainty:*: Raw 0.70; population weight 0.80; discounted 0.56.

77 Kulin et al. 2026 — GI Symptoms and Comorbidities in POTS: Meta-Analysis

*Full Citation:*: Kulin D, Shah A, Fairlie T, et al.\ Gastrointestinal Symptoms and Systemic Comorbidities in Patients With POTS: A Systematic Review and Meta-Analysis. *Neurogastroenterology & Motility*. 2026;38(4):e70305. [@Kulin2026POTSGIMeta]
*DOI:*: [10.1111/nmo.70305](https://doi.org/10.1111/nmo.70305)
*PMID:*: 41952073
*Study Design:*: Systematic review and meta-analysis
*Sample Size:*: 19 studies, 8268 POTS patients
*Key Findings:*:
    - 36.3% (95% CI 17.8-60.0) of POTS patients report comorbid mast cell activation syndrome (MCAS)
    - 31% report joint hypermobility syndrome
    - 40.9% report chronic fatigue
*Conclusion:*: A large MCAS-overlap subset exists within POTS/dysautonomia — the population in whom mediator-arm drug probes would be informative.
*Limitations:*: Substantial heterogeneity; self-report MCAS diagnosis.
*Certainty:*: Raw 0.75 (meta-analysis); population weight 0.80; discounted 0.60.

78 Rehman et al. 2026 — Rupatadine for Allergic Rhinitis: Meta-Analysis

*Full Citation:*: Rehman A, Ihtesham A, Raja HAA, et al.\ Efficacy and safety of rupatadine in allergic rhinitis: a systematic review and meta-analysis of randomized controlled trials. *Annals of Medicine and Surgery*. 2026;88(7):4410-4420. [@Rehman2026RupatadineMeta]
*DOI:*: [10.1097/MS9.0000000000004930](https://doi.org/10.1097/MS9.0000000000004930)
*PMID:*: 42433781
*Study Design:*: Meta-analysis of RCTs
*Sample Size:*: 8 RCTs, 2442 participants
*Key Findings:*:
    - Rupatadine (dual H1 + platelet-activating-factor antagonist) significantly reduces nasal symptoms
    - Somnolence is the most common adverse event; no serious adverse events
    - Dose-response trend favours 20 mg over 10 mg
*Conclusion:*: Establishes rupatadine's dual-arm pharmacology and the central-H1 sedation side-effect relevant to the histamine-arousal bridge.
*Limitations:*: Allergic rhinitis population; quality-of-life benefit inconclusive.
*Certainty:*: Raw 0.75; population general weight 0.75; discounted 0.56.

79 Ortiz et al. 2026 — Acupressure and Hypnosis: A Series of N-of-1 Trials

*Full Citation:*: Ortiz M, Schreiner MM, Volz N, et al.\ Acupressure and hypnosis in arterial hypertension: a series of N-of-1 trials. *Frontiers in Medicine*. 2026;13:1871793. [@Ortiz2026Nof1Trials]
*DOI:*: [10.3389/fmed.2026.1871793](https://doi.org/10.3389/fmed.2026.1871793)
*PMID:*: 42676430
*Study Design:*: Series of N-of-1 randomized trials
*Sample Size:*: 17 patients
*Key Findings:*:
    - High feasibility and adherence (over 90%)
    - No overall group effect in the meta-analysis, while selected individuals responded
*Conclusion:*: Individual response heterogeneity can coexist with a null group mean — the core methodological basis for non-response/responder-subset fingerprinting.
*Limitations:*: Small n; hypertension, not MCAS/ME/CFS.
*Certainty:*: Raw 0.55; population weight 0.75; discounted 0.41.

80 Abbotts et al. 2025 — Histamine-Receptor Blockade and Exercise (Null)

*Full Citation:*: Abbotts KSS, Hudgins JH, Viveros IS, et al.\ Histamine-receptor blockade does not influence the heavy-severe domain boundary and time to task failure in the severe domain during cycling exercise in adults. *Physiological Reports*. 2025;13(19):e70587. [@Abbotts2025HistamineExercise]
*DOI:*: [10.14814/phy2.70587](https://doi.org/10.14814/phy2.70587)
*PMID:*: 41017413
*Study Design:*: Double-blind randomized crossover
*Sample Size:*: 17 participants
*Key Findings:*:
    - Histamine-receptor blockade did not change the heavy-severe exercise domain boundary (p = 0.41)
    - No change in time to task failure (p = 0.95)
*Conclusion:*: NULL result — histamine is not required to sustain short-duration severe-domain exercise in healthy adults; constrains a simple histamine-to-exercise-capacity coupling.
*Limitations:*: Small n; healthy adults; short exercise protocol.
*Certainty:*: Raw 0.60 (RCT, small n); population weight 0.75; discounted 0.45.

81 Kay 2000 — Effects of Antihistamines on Cognition and Performance

*Full Citation:*: Kay GG. The effects of antihistamines on cognition and performance. *Journal of Allergy and Clinical Immunology*. 2000;105(6 Pt 2):S622-S627. [@Kay2000AntihistamineCognition]
*DOI:*: [10.1067/mai.2000.106153](https://doi.org/10.1067/mai.2000.106153)
*PMID:*: 10856168
*Study Design:*: Review
*Key Findings:*:
    - First-generation H1 antihistamines are lipophilic, cross the blood-brain barrier, and impair divided attention, working memory, vigilance and speed
    - Second-generation agents (e.g. loratadine) are largely non-sedating
*Conclusion:*: Central H1 blockade impairs wakefulness and performance — the pharmacological basis for histamine as a wake-promoting (anti-fatigue) signal.
*Limitations:*: Review; healthy/allergy populations.
*Certainty:*: Raw 0.60; population weight 0.75; discounted 0.45.

82 Jones 2020 — Arousal and Sleep Circuits

*Full Citation:*: Jones BE. Arousal and sleep circuits. *Neuropsychopharmacology*. 2020;45(1):6-20. [@Jones2020ArousalCircuits]
*DOI:*: [10.1038/s41386-019-0444-2](https://doi.org/10.1038/s41386-019-0444-2)
*PMID:*: 31216564
*Study Design:*: Review
*Key Findings:*:
    - Wake-promoting neuromodulatory systems include acetylcholine, noradrenaline, dopamine, serotonin, histamine and orexin
    - These systems discharge maximally during waking
*Conclusion:*: Positions histamine within the canonical arousal circuit that is plausibly dysregulated in "wired but tired" states.
*Limitations:*: General neuroscience review.
*Certainty:*: Raw 0.60; population weight 0.75; discounted 0.45.

83 Niijima-Yaoita et al. 2012 — Roles of Histamine in Exercise-Induced Fatigue

*Full Citation:*: Niijima-Yaoita F, Tsuchiya M, Ohtsu H, et al.\ Roles of histamine in exercise-induced fatigue: favouring endurance and protecting against exhaustion. *Biological & Pharmaceutical Bulletin*. 2012;35(1):91-97. [@NiijimaYaoita2012HistamineFatigue]
*DOI:*: [10.1248/bpb.35.91](https://doi.org/10.1248/bpb.35.91)
*PMID:*: 22223343
*Study Design:*: Animal study (mice)
*Key Findings:*:
    - Histamine (via histidine decarboxylase / H1) favours endurance and protects against exercise exhaustion
    - H1 blockade or histamine deficiency impairs endurance
*Conclusion:*: Directly supports the histamine-as-compensation premise — H1 blockade can unmask fatigue.
*Limitations:*: Mouse study; translation gap.
*Certainty:*: Raw 0.50 (animal); population weight 0.50; discounted 0.25.

84 Nikolaeva-Koleva et al. 2021 — TRPV1-Mediated Histaminergic Neuron Excitability

*Full Citation:*: Nikolaeva-Koleva M, Butron L, González-Rodríguez S, et al.\ A capsaicinoid-based soft drug, AG1529, for attenuating TRPV1-mediated histaminergic and inflammatory sensory neuron excitability. *Scientific Reports*. 2021;11(1):246. [@NikolaevaKoleva2021HistamineTRPV1]
*DOI:*: [10.1038/s41598-020-80725-z](https://doi.org/10.1038/s41598-020-80725-z)
*PMID:*: 33420359
*Study Design:*: In vitro (DRG) + rodent pruritus model
*Key Findings:*:
    - The TRPV1 antagonist AG1529 abolished histaminergic and inflammation-mediated TRPV1 sensitization in primary DRG neuron cultures
    - Attenuated histaminergic itch in vivo
*Conclusion:*: Directly demonstrates histamine sensitizes TRPV1 nociceptors — the molecular basis for an H1-to-TRPV1 pain bridge.
*Limitations:*: Preclinical; no human pain outcome.
*Certainty:*: Raw 0.50 (in vitro + animal); population weight 0.40; discounted 0.20.

85 Kalangara et al. 2022 — Neuropathic Pain and Itch in Allergic Conjunctivitis

*Full Citation:*: Kalangara JP, Vanijcharoenkarn K, Chisolm S, Kuruvilla ME. Neuropathic pain and itch: mechanisms in allergic conjunctivitis. *Current Opinion in Allergy and Clinical Immunology*. 2022;22(5):298-303. [@Kalangara2022TRPV1Histamine]
*DOI:*: [10.1097/ACI.0000000000000843](https://doi.org/10.1097/ACI.0000000000000843)
*PMID:*: 35916592
*Study Design:*: Review
*Key Findings:*:
    - Ocular surface contains TRPV1+ (histamine-dependent) and TRPA1+ (histamine-independent) neurons
    - Mast cell mediators directly activate C fibres; repeated activation produces peripheral and central sensitization
*Conclusion:*: Frames histamine-to-TRPV1 sensitization within mast-cell-driven neurogenic pain.
*Limitations:*: Review; ocular allergy focus.
*Certainty:*: Raw 0.55; population weight 0.75; discounted 0.41.

86 Chen et al. 2023 — Antihistamines Exert Anti-Nociceptive Effects in Mice

*Full Citation:*: Chen Y, Xiao X, Huang C, et al.\ Flupirtine and antihistamines exert synergistic anti-nociceptive effects in mice. *Psychopharmacology*. 2023;240(4):881-897. [@Chen2023AntihistamineAnalgesia]
*DOI:*: [10.1007/s00213-023-06329-3](https://doi.org/10.1007/s00213-023-06329-3)
*PMID:*: 36752814
*Study Design:*: Animal study (mice)
*Key Findings:*:
    - Antihistamines (promethazine, fexofenadine) exert anti-nociceptive effects in inflammatory and neuropathic pain models
    - Effects partially mediated by Kv7/M potassium channels (reversed by XE991)
*Conclusion:*: Independent evidence that H1 antagonists reduce pain, complementing the TRPV1-sensitization route.
*Limitations:*: Mouse models; Kv7-mediated, not clearly TRPV1-mediated.
*Certainty:*: Raw 0.50 (animal); population weight 0.50; discounted 0.25.

87 Sakurai et al. 2021 — Interaction Between Orexin Neurons and Monoaminergic Systems

*Full Citation:*: Sakurai T, Saito YC, Yanagisawa M. Interaction between Orexin Neurons and Monoaminergic Systems. *Frontiers of Neurology and Neuroscience*. 2021;45:11-21. [@Sakurai2021OrexinMonoamine]
*DOI:*: [10.1159/000514955](https://doi.org/10.1159/000514955)
*PMID:*: 34052806
*Study Design:*: Review
*Key Findings:*:
    - Orexin neurons act primarily on monoaminergic neurons — including histaminergic tuberomammillary neurons — to maintain arousal and vigilance
*Conclusion:*: Documents the orexin-to-histamine arousal relay, the circuit basis for a histamine-orexin "wired but tired" mismatch.
*Limitations:*: General neuroscience review.
*Certainty:*: Raw 0.55; population weight 0.75; discounted 0.41.

88 Pedersen et al. 2026 — Wake-Promoting Neuromodulators in Alzheimer’s Disease

*Full Citation:*: Pedersen TJ, Clemens SG, Winer JR, et al.\ Wake-promoting neuromodulators in Alzheimer's disease: Implications for sleep and brain clearance. *Alzheimer's & Dementia*. 2026;22(3):e71298. [@Pedersen2026WakeNeuromodulators]
*DOI:*: [10.1002/alz.71298](https://doi.org/10.1002/alz.71298)
*PMID:*: 41830117
*Study Design:*: Review
*Key Findings:*:
    - Norepinephrine, histamine and orexin are wake-promoting neuromodulators linked to sleep and glymphatic clearance
    - Their dysfunction may drive a cycle of sleep disruption, impaired clearance and neurodegeneration
*Conclusion:*: Extends the histamine/orexin arousal circuit to a clearance consequence relevant to brain-fog mechanisms.
*Limitations:*: Alzheimer's focus; extrapolation to ME/CFS.
*Certainty:*: Raw 0.55; population weight 0.75; discounted 0.41.

89 Baker et al. 2023 — Microclots/Aggregates Reduce After Anticoagulation

*Full Citation:*: Baker SR, Halliday G, Ząbczyk M, et al.\ Plasma from patients with pulmonary embolism show aggregates that reduce after anticoagulation. *Communications Medicine*. 2023;3(1):12. [@Baker2023MicroclotPE]
*DOI:*: [10.1038/s43856-023-00242-8](https://doi.org/10.1038/s43856-023-00242-8)
*PMID:*: 36709220
*Study Design:*: Cohort study
*Sample Size:*: 35 pulmonary embolism patients
*Key Findings:*:
    - Microclot/amyloid-fibrin(ogen) aggregates in plasma are composed of fibrin and platelets
    - Reduced by low-molecular-weight heparin
*Conclusion:*: Establishes the platelet + fibrin composition of microclots — the substrate a PAF antagonist (platelet activator) would theoretically modulate.
*Limitations:*: PE patients, not ME/CFS/long COVID.
*Certainty:*: Raw 0.55 (n=35); population weight 0.75; discounted 0.41.

90 Hung et al. 2025 — Competitive Inhibition of the PAF Receptor by Acyl-PAF

*Full Citation:*: Hung SC, Chen CC, Chan HC, et al.\ Structural and molecular dynamics insights into the competitive inhibition of the platelet-activating factor receptor by acyl-PAF. *Journal of Biological Chemistry*. 2025;301(12):110831. [@Hung2025PAFReceptor]
*DOI:*: [10.1016/j.jbc.2025.110831](https://doi.org/10.1016/j.jbc.2025.110831)
*PMID:*: 41109342
*Study Design:*: Structural biology (in vitro)
*Key Findings:*:
    - Molecular pharmacology of PAF-receptor competitive inhibition by acyl-PAF
*Conclusion:*: Establishes the druggable PAF-receptor target — the second arm of rupatadine that links mast-cell PAF release to platelet activation.
*Limitations:*: In vitro structural; no clinical data.
*Certainty:*: Raw 0.50 (in vitro); population weight 0.40; discounted 0.20.

91 Flores 2026 — Rupatadine Add-On for Dengue Hemorrhagic Fever (Case)

*Full Citation:*: Flores ME. Rupatadine as an Add-On Therapy for Dengue Hemorrhagic Fever: A Case Report. *Cureus*. 2026;18(4):e106343. [@Flores2026RupatadineDengue]
*DOI:*: [10.7759/cureus.106343](https://doi.org/10.7759/cureus.106343)
*PMID:*: 42083698
*Study Design:*: Case report
*Key Findings:*:
    - PAF is elevated in dengue hemorrhagic fever and drives vascular permeability
    - Rupatadine used as a PAF antagonist
*Conclusion:*: Illustrates the clinical logic of targeting PAF-mediated vascular/platelet pathology with rupatadine's PAF arm.
*Limitations:*: Single case; dengue, not ME/CFS.
*Certainty:*: Raw 0.30 (case report); population weight 0.75; discounted 0.23.

92 Fong et al. 2025 — In Silico Modelling of FDA Drugs Targeting T-Type Calcium Channels

*Full Citation:*: Fong P, Garcia SR, Stefan MI, Sterratt DC. In Silico identification and modelling of FDA-approved drugs targeting T-type calcium channels. *PLOS ONE*. 2025;20(8):e0327386. [@Fong2025MontelukastBBB]
*DOI:*: [10.1371/journal.pone.0327386](https://doi.org/10.1371/journal.pone.0327386)
*PMID:*: 40779495
*Study Design:*: In silico drug screen
*Key Findings:*:
    - Montelukast identified as a high-affinity Cav3.1 T-type calcium-channel binder
    - Has drug-like properties to cross the human blood-brain barrier and reach synapses
*Conclusion:*: Computational support for montelukast as the CNS-penetrant member of the MCAS stack.
*Limitations:*: In silico only; no empirical CNS readout.
*Certainty:*: Raw 0.40 (in silico); population weight 0.30; discounted 0.12.

93 Zhou et al. 2019 — Montelukast Protects Against Blood-Brain Barrier Injury

*Full Citation:*: Zhou L, Sun X, Shi Y, Liu J, Luan G, Yang Y. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier. *Inflammopharmacology*. 2019;27(5):933-940. [@Zhou2019MontelukastBBB]
*DOI:*: [10.1007/s10787-019-00611-7](https://doi.org/10.1007/s10787-019-00611-7)
*PMID:*: 31313075
*Study Design:*: In vitro + murine MCAO model
*Key Findings:*:
    - Montelukast suppressed OGD/R-induced BBB permeability; restored occludin/ZO-1
    - Reduced MMP-2/9 and IL-1β/TNF-α/IL-6; improved brain injury in vivo
*Conclusion:*: Establishes CysLT1 in brain-endothelial/BBB pathophysiology — the "brain MCAS" target of montelukast.
*Limitations:*: Preclinical; stroke model.
*Certainty:*: Raw 0.50 (in vitro + animal); population weight 0.50; discounted 0.25.

94 Amezola-Herrera et al. 2026 — Sleep Disorders Associated With Montelukast (HARM)

*Full Citation:*: Amezola-Herrera E, Galindo-Pacheco LV, Sosa-Bustamante GP, et al.\ Sleep disorders associated with montelukast in children with respiratory allergy. *Revista Medica del Instituto Mexicano del Seguro Social*. 2026;64(5):e7135. [@AmezolaHerrera2026MontelukastSleep]
*DOI:*: [10.5281/zenodo.21462729](https://doi.org/10.5281/zenodo.21462729)
*PMID:*: 42771719
*Study Design:*: Prospective cohort
*Sample Size:*: 120 children (60 montelukast users, 60 controls)
*Key Findings:*:
    - 73.02% of montelukast users had sleep disorders vs 14.17% of non-users
    - Association OR 8.31, p = 0.0001
*Conclusion:*: HARM SIGNAL — montelukast is associated with sleep disruption, consistent with its CNS activity.
*Limitations:*: Pediatric respiratory-allergy population; observational.
*Certainty:*: Raw 0.55 (cohort); population weight 0.75; discounted 0.41.

95 Redfern & Smith 2026 — A Quarter-Century of Montelukast (HARM)

*Full Citation:*: Redfern JS, Smith MA. A quarter-century of montelukast: clinical lessons for adult and pediatric asthma and allergic rhinitis care. *Current Medical Research and Opinion*. 2026;42(6):1179-1194. [@Redfern2026MontelukastQuarter]
*DOI:*: [10.1080/03007995.2026.2700973](https://doi.org/10.1080/03007995.2026.2700973)
*PMID:*: 42466635
*Study Design:*: Review
*Key Findings:*:
    - Infrequent but potentially serious neuropsychiatric adverse events led to strengthened regulatory warnings
    - Guidelines now position montelukast as add-on rather than first-line
*Conclusion:*: Documents the CNS side-effect burden that doubles as evidence of central leukotriene activity — a safety caveat for any "brain MCAS" framing.
*Limitations:*: Review.
*Certainty:*: Raw 0.60 (review); population weight 0.75; discounted 0.45.

96 Smolensky et al. 2007 — Chronobiology and Chronotherapy of Allergic Rhinitis and Asthma

*Full Citation:*: Smolensky MH, Lemmer B, Reinberg AE. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. *Advanced Drug Delivery Reviews*. 2007;59(9-10):852-882. [@Smolensky2007Chronotherapy]
*DOI:*: [10.1016/j.addr.2007.08.016](https://doi.org/10.1016/j.addr.2007.08.016)
*PMID:*: 17900748
*Study Design:*: Authoritative narrative review of chronobiology/chronotherapy of allergic disease.
*Certainty / population / discounted:*: raw 0.60 | general 0.75 | discounted 0.45
*Key Findings:*:
    - Allergic rhinitis and asthma symptoms show a well-documented nocturnal/early-morning peak (histamine and other mediators are elevated at night).
    - Antihistamines and asthma controllers show time-of-day-dependent efficacy (chronotherapy); evening dosing of leukotriene antagonists is standard to cover the nocturnal peak.
*Conclusion:*: Timing antihistamine/anti-leukotriene dosing to the circadian mediator peak improves control at equal dose.
*Limitations:*: Narrative review; no ME/CFS-specific data; general allergy/asthma populations.

97 Kurokawa et al. 2001 — Circadian Characteristics of Urinary Leukotriene E4

*Full Citation:*: Kurokawa K, Tanaka H, Tanaka S, Abe S. Circadian characteristics of urinary leukotriene E(4) in healthy subjects and nocturnal asthmatic patients. *Chest*. 2001;120(6):1822-1828. [@Kurokawa2001LeukotrieneE4]
*DOI:*: [10.1378/chest.120.6.1822](https://doi.org/10.1378/chest.120.6.1822)
*PMID:*: 11742908
*Study Design:*: Observational diurnal sampling of urinary LTE4 (cysteinyl-leukotriene metabolite).
*Certainty / population / discounted:*: raw 0.50 | general 0.75 | discounted 0.38
*Key Findings:*:
    - Urinary LTE4 (a marker of cysteinyl-leukotriene production) shows a circadian rhythm with a nocturnal/early-morning peak in both healthy and asthmatic subjects.
    - This leukotriene peak parallels the nocturnal worsening of asthma.
*Conclusion:*: Cysteinyl-leukotriene production peaks at night, providing the mechanistic basis for evening (PM) montelukast dosing.
*Limitations:*: Small sample; surrogate urinary metabolite; general population.

98 Tanaka et al. 2003 — Early-Morning Urinary LTE4 in Nocturnal Asthma

*Full Citation:*: Tanaka S, Tanaka H, Abe S. High dose of inhaled fluticasone reduces high levels of urinary leukotriene E4 in the early morning in mild and moderate nocturnal asthma. *Chest*. 2003;124(5):1768-1773. [@Tanaka2003NocturnalLTE4]
*DOI:*: [10.1378/chest.124.5.1768](https://doi.org/10.1378/chest.124.5.1768)
*PMID:*: 14605047
*Study Design:*: Clinical observational, nocturnal asthma cohort.
*Certainty / population / discounted:*: raw 0.50 | general 0.75 | discounted 0.38
*Key Findings:*:
    - Early-morning urinary LTE4 is elevated in nocturnal asthma; corticosteroid treatment lowers it in parallel with symptom improvement.
*Conclusion:*: Nocturnal leukotriene overproduction tracks nocturnal airway symptoms.
*Limitations:*: Asthma-specific; surrogate marker; no mast-cell-timing data.

99 Ochfeld et al. 2021 — Diurnal Variations in Skin Prick Testing

*Full Citation:*: Ochfeld E, Cheng B, Bowsher N, Fishbein A. Diurnal Variations in Skin Prick Testing. *Pediatric Allergy, Immunology, and Pulmonology*. 2021;34(4):125-129. [@Ochfeld2021DiurnalSPT]
*DOI:*: [10.1089/ped.2021.0055](https://doi.org/10.1089/ped.2021.0055)
*PMID:*: 34714138
*Study Design:*: Observational, diurnal skin-prick-test reactivity.
*Certainty / population / discounted:*: raw 0.45 | general 0.75 | discounted 0.34
*Key Findings:*:
    - Skin-prick-test wheal size varies by time of day, consistent with a circadian rhythm in cutaneous histamine responsiveness.
*Conclusion:*: Cutaneous mast-cell/histamine reactivity has a circadian component.
*Limitations:*: Small; pediatric; surrogate (SPT reactivity, not direct histamine level).

100 Mochizuki 2022 — Histamine as an Alert Signal in the Brain

*Full Citation:*: Mochizuki T. Histamine as an Alert Signal in the Brain. *Current Topics in Behavioral Neurosciences*. 2022;59:413-425. [@Mochizuki2022HistamineAlert]
*DOI:*: [10.1007/7854_2021_249](https://doi.org/10.1007/7854_2021_249)
*PMID:*: 34448132
*Study Design:*: Narrative review of central histamine and wakefulness.
*Certainty / population / discounted:*: raw 0.50 | general 0.75 | discounted 0.38
*Key Findings:*:
    - Histamine is a wake-promoting alert signal; histaminergic neuron activity is highest during wakefulness and falls during sleep.
    - Central histamine and peripheral (mast-cell) histamine operate on different schedules, complicating any single "histamine peak" model.
*Conclusion:*: Histamine timing is system-dependent; central arousal histamine peaks during wake, while peripheral mediator histamine peaks at night.
*Limitations:*: Review; CNS-focus; no ME/CFS data.

101 Lemmer 2005 — Chronopharmacology and Controlled Drug Release

*Full Citation:*: Lemmer B. Chronopharmacology and controlled drug release. *Expert Opinion on Drug Delivery*. 2005;2(4):667-681. [@Lemmer2005Chronopharmacology]
*DOI:*: [10.1517/17425247.2.4.667](https://doi.org/10.1517/17425247.2.4.667)
*PMID:*: 16296793
*Study Design:*: Narrative review.
*Certainty / population / discounted:*: raw 0.50 | general 0.75 | discounted 0.38
*Key Findings:*:
    - Drug response varies by circadian phase; chronotherapy (timing dosing to the disease's circadian peak) improves outcome for several drug classes.
*Conclusion:*: Chronopharmacology is a general principle applicable to antihistamines and leukotriene antagonists.
*Limitations:*: General pharmacology; no disease-specific mast-cell data.

102 Raj et al. 2005 — Acetylcholinesterase Inhibition Improves Tachycardia in POTS

*Full Citation:*: Raj SR, Black BK, Biaggioni I, Harris PA. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. *Circulation*. 2005;111(21):2734-2740. [@Raj2005PyridostigminePOTS]
*DOI:*: [10.1161/CIRCULATIONAHA.104.497594](https://doi.org/10.1161/CIRCULATIONAHA.104.497594)
*PMID:*: 15911704
*Study Design:*: Open-label, n=17 POTS patients; pyridostigmine 30 mg.
*Certainty / population / discounted:*: raw 0.55 | POTS 0.80 | discounted 0.44
*Key Findings:*:
    - Pyridostigmine (30 mg) reduced standing heart rate but did not improve symptoms at that dose; muscarinic side effects (abdominal cramping, urgency) emerged.
    - Defines the low-dose cholinergic side-effect threshold.
*Conclusion:*: Pyridostigmine narrows the tachycardia window in POTS but has a tight cholinergic side-effect ceiling.
*Limitations:*: Open-label; small n; single dose; no ME/CFS cohort.

103 Schl{"o}mer et al. 2025 — Pyridostigmine Improves Hand Grip Strength in ME/CFS

*Full Citation:*: Schl{\"o}mer E, Stein E, Kedor C, Rust R. Pyridostigmine improves hand grip strength in patients with myalgic encephalomyelitis/chronic fatigue syndrome. *Frontiers in Neuroscience*. 2025;19:1637838. [@Schlomer2025PyridostigmineMECFS]
*DOI:*: [10.3389/fnins.2025.1637838](https://doi.org/10.3389/fnins.2025.1637838)
*PMID:*: 40970182
*Study Design:*: Prospective pilot in ME/CFS patients (direct target population).
*Certainty / population / discounted:*: raw 0.55 | ME/CFS 1.00 | discounted 0.55
*Key Findings:*:
    - Pyridostigmine improved hand-grip strength in ME/CFS patients, implicating a cholinergic/muscarinic-reversible deficit.
    - Tolerability was limited by dose-dependent cholinergic side effects, defining a practical therapeutic window.
*Conclusion:*: Direct ME/CFS signal that pyridostigmine's benefit/side-effect gap defines a cholinergic reserve index.
*Limitations:*: Pilot; small n; grip strength is a single endpoint; not yet independently replicated.

104 Okamoto et al. 2025 — Clinical Correlates of Pyridostigmine Efficacy in Orthostatic Hypotension

*Full Citation:*: Okamoto LE, Walsh E, Diedrich A, Shibao CA. Clinical Correlates of Efficacy of Pyridostigmine in the Treatment of Orthostatic Hypotension. *Hypertension*. 2025;82(3):489-497. [@Okamoto2025PyridostigmineOH]
*DOI:*: [10.1161/HYPERTENSIONAHA.124.24050](https://doi.org/10.1161/HYPERTENSIONAHA.124.24050)
*PMID:*: 39727053
*Study Design:*: Cohort study of pyridostigmine responders/non-responders in orthostatic hypotension.
*Certainty / population / discounted:*: raw 0.60 | autonomic 0.80 | discounted 0.48
*Key Findings:*:
    - Pyridostigmine pressor efficacy varies between patients; clinical correlates (baseline autonomic function) predict response and tolerability.
*Conclusion:*: Individual cholinergic reserve shapes both efficacy and the side-effect ceiling.
*Limitations:*: Orthostatic-hypotension population; no ME/CFS data.

105 Okamoto et al. 2019 — Synergistic Pressor Effect of Atomoxetine and Pyridostigmine

*Full Citation:*: Okamoto LE, Shibao CA, Gamboa A, Diedrich A. Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension. *Hypertension*. 2019;73(1):235-241. [@Okamoto2019AtomoxetinePyrido]
*DOI:*: [10.1161/HYPERTENSIONAHA.118.11790](https://doi.org/10.1161/HYPERTENSIONAHA.118.11790)
*PMID:*: 30571543
*Study Design:*: Interventional, autonomic-failure cohort.
*Certainty / population / discounted:*: raw 0.55 | autonomic 0.80 | discounted 0.44
*Key Findings:*:
    - Pyridostigmine and atomoxetine combined produce a greater pressor effect than either alone, implying additive cholinergic + noradrenergic mechanisms.
*Conclusion:*: Cholinergic augmentation interacts with adrenergic tone — relevant to combined-antagonist stacking.
*Limitations:*: Neurogenic OH population; small.

106 Shibao et al. 2010 — Yohimbine vs Pyridostigmine in Autonomic Failure

*Full Citation:*: Shibao CA, Okamoto LE, Gamboa A, Yu C. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. *Hypertension*. 2010;56(5):847-851. [@Shibao2010YohimbinePyrido]
*DOI:*: [10.1161/HYPERTENSIONAHA.110.154898](https://doi.org/10.1161/HYPERTENSIONAHA.110.154898)
*PMID:*: 20837887
*Study Design:*: Comparative interventional study.
*Certainty / population / discounted:*: raw 0.55 | autonomic 0.80 | discounted 0.44
*Key Findings:*:
    - Pyridostigmine and yohimbine differ in pressor efficacy and side-effect profile, confirming a drug-specific cholinergic vs adrenergic balance.
*Conclusion:*: Cholinergic vs adrenergic strategies have distinct efficacy/tolerability trade-offs.
*Limitations:*: Autonomic-failure cohort; no ME/CFS data.

107 Seng et al. 2026 — Rebound Pruritus and Urticaria After Antihistamine Discontinuation (Scoping Review)

*Full Citation:*: Seng JJB, Oka P, Tan NC. Rebound Pruritus and Urticaria After Discontinuation of Chronic Antihistamine Use — A Scoping Review. *Clinical and Experimental Allergy*. 2026. [@Seng2026ReboundReview]
*DOI:*: [10.1111/cea.70291](https://doi.org/10.1111/cea.70291)
*PMID:*: 41911848
*Study Design:*: Scoping review of rebound after chronic H1-antihistamine cessation.
*Certainty / population / discounted:*: raw 0.60 | general 0.75 | discounted 0.45
*Key Findings:*:
    - Chronic H1-antihistamine use, especially cetirizine/levocetirizine, can be followed by rebound pruritus and urticaria on discontinuation.
    - Supports a withdrawal/tachyphylaxis phenomenon consistent with H1-receptor upregulation.
*Conclusion:*: Antihistamine rebound is a documented clinical entity — supports E3's withdrawal-rebound arm.
*Limitations:*: Scoping review; heterogeneous case evidence; no ME/CFS data.

108 Seng et al. 2025 — Rebound After Chronic Cetirizine Use (Case Report)

*Full Citation:*: Seng JJB, Cai M, Oka P. Rebound Pruritus and Urticaria Post-discontinuation of Chronic Cetirizine Use: A Case Report. *Cureus*. 2025;17(12):e100214. [@Seng2025CetirizineRebound]
*DOI:*: [10.7759/cureus.100214](https://doi.org/10.7759/cureus.100214)
*PMID:*: 41602253
*Study Design:*: Case report.
*Certainty / population / discounted:*: raw 0.35 | general 0.75 | discounted 0.26
*Key Findings:*:
    - A patient developed rebound pruritus/urticaria after stopping chronic cetirizine, resolving with taper.
*Conclusion:*: Individual-level illustration of the rebound mechanism.
*Limitations:*: Single case; anecdotal.

109 Richardson et al. 2002 — Tolerance to Daytime Sedative Effects of H1 Antihistamines

*Full Citation:*: Richardson GS, Roehrs TA, Rosenthal L, Koshorek G. Tolerance to daytime sedative effects of H1 antihistamines. *Journal of Clinical Psychopharmacology*. 2002;22(5):511-515. [@Richardson2002H1Tolerance]
*DOI:*: [10.1097/00004714-200210000-00012](https://doi.org/10.1097/00004714-200210000-00012)
*PMID:*: 12352276
*Study Design:*: Controlled repeated-dose study in healthy volunteers.
*Certainty / population / discounted:*: raw 0.50 | general 0.75 | discounted 0.38
*Key Findings:*:
    - The sedative (H1-mediated) effect of antihistamines shows tolerance/tachyphylaxis with repeated dosing.
*Conclusion:*: H1-antihistamine tachyphylaxis is demonstrable for central H1 effects — supports the tolerance arm of E3.
*Limitations:*: Healthy volunteers; sedation endpoint only.

110 Fukui 2007 — Targeting Histamine H1 Receptor Gene Expression

*Full Citation:*: Fukui H. Role of therapeutics for allergic diseases in targeting histamine H1 receptor gene expression. *Yakugaku Zasshi*. 2007;127(1):15-25. [@Fukui2007H1GeneExpression]
*DOI:*: [10.1248/yakushi.127.15](https://doi.org/10.1248/yakushi.127.15)
*PMID:*: 17202781
*Study Design:*: Mechanistic review of H1-receptor expression regulation.
*Certainty / population / discounted:*: raw 0.45 | general 0.75 | discounted 0.34
*Key Findings:*:
    - H1-antihistamines modulate H1-receptor gene expression; sustained blockade can upregulate receptor expression, a molecular basis for tolerance and rebound.
*Conclusion:*: H1-receptor upregulation provides a mechanistic substrate for antihistamine tachyphylaxis.
*Limitations:*: Review; predominantly in vitro/preclinical.

111 Miyoshi et al. 2006 — Regulation of H1 Receptor Signaling by Expression Level

*Full Citation:*: Miyoshi K, Das AK, Fujimoto K, Horio S. Recent advances in molecular pharmacology of the histamine systems: regulation of histamine H1 receptor signaling by changing its expression level. *Journal of Pharmacological Sciences*. 2006;101(1):3-6. [@Miyoshi2006H1Receptor]
*DOI:*: [10.1254/jphs.fmj06001x2](https://doi.org/10.1254/jphs.fmj06001x2)
*PMID:*: 16648669
*Study Design:*: Mechanistic review.
*Certainty / population / discounted:*: raw 0.45 | general 0.75 | discounted 0.34
*Key Findings:*:
    - H1-receptor signaling is tuned by receptor expression level; antagonist exposure shifts expression, linking blockade to altered sensitivity.
*Conclusion:*: Receptor-expression plasticity underlies antihistamine tolerance/rebound.
*Limitations:*: Review; no clinical dosing data.

112 Smit et al. 1996 — Inverse Agonism and H2-Receptor Upregulation (PNAS)

*Full Citation:*: Smit MJ, Leurs R, Alewijnse AE, Blauw J. Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors. *Proceedings of the National Academy of Sciences*. 1996;93(13):6802-6807. [@Smit1996H2InverseAgonism]
*DOI:*: [10.1073/pnas.93.13.6802](https://doi.org/10.1073/pnas.93.13.6802)
*PMID:*: 8692899
*Study Design:*: In vitro mechanistic (cell lines).
*Certainty / population / discounted:*: raw 0.55 | in vitro 0.40 | discounted 0.22
*Key Findings:*:
    - H2 antagonists acting as inverse agonists upregulate spontaneously active H2 receptors — a molecular mechanism for receptor-compensation on chronic blockade.
*Conclusion:*: Receptor upregulation on antagonist exposure is a general (H1 and H2) phenomenon supporting tachyphylaxis/rebound reasoning.
*Limitations:*: In vitro; H2-focused.

113 Xu et al. 2020 — GPER-Mediated Estrogen-Dependent Visceral Hypersensitivity and Mast Cells

*Full Citation:*: Xu S, Wang X, Zhao J, Yang S. GPER-mediated, oestrogen-dependent visceral hypersensitivity in stressed rats is associated with mast cell tryptase and histamine expression. *Fundamental \& Clinical Pharmacology*. 2020;34(4):433-443. [@Xu2020GPERMastCell]
*DOI:*: [10.1111/fcp.12537](https://doi.org/10.1111/fcp.12537)
*PMID:*: 31967341
*Study Design:*: Animal (rat) mechanistic study.
*Certainty / population / discounted:*: raw 0.50 | animal 0.50 | discounted 0.25
*Key Findings:*:
    - Estrogen (via GPER) increases mast-cell tryptase and histamine expression and drives visceral hypersensitivity in stressed rats.
*Conclusion:*: Estrogen-dependent mast-cell mediator upregulation has an in vivo correlate.
*Limitations:*: Rodent; stress model.

114 Chen et al. 2008 — Gender, Sex Hormones, and Immediate-Type Hypersensitivity

*Full Citation:*: Chen W, Mempel M, Schober W, Behrendt H. Gender difference, sex hormones, and immediate type hypersensitivity reactions. *Allergy*. 2008;63(11):1418-1427. [@Chen2008SexHormones]
*DOI:*: [10.1111/j.1398-9995.2008.01880.x](https://doi.org/10.1111/j.1398-9995.2008.01880.x)
*PMID:*: 18925878
*Study Design:*: Review of sex-hormone effects on hypersensitivity/mast cells.
*Certainty / population / discounted:*: raw 0.55 | general 0.75 | discounted 0.41
*Key Findings:*:
    - Estrogen enhances mast-cell activity and immediate hypersensitivity; symptom severity can track the menstrual cycle (perimenstrual worsening).
*Conclusion:*: Estrogen-driven mast-cell reactivity supports cycle-synchronised dosing as a plausible strategy.
*Limitations:*: Review; general allergy population.

115 Kasperska-Zaj{}c et al. 2008 — Sex Hormones and Urticaria

*Full Citation:*: Kasperska-Zaj{\c a}c A, Brzoza Z, Rogala B. Sex hormones and urticaria. *Journal of Dermatological Science*. 2008;52(2):79-86. [@KasperskaZajac2008SexHormonesUrticaria]
*DOI:*: [10.1016/j.jdermsci.2008.04.002](https://doi.org/10.1016/j.jdermsci.2008.04.002)
*PMID:*: 18485675
*Study Design:*: Review of sex-hormone influence on urticaria (a mast-cell disease).
*Certainty / population / discounted:*: raw 0.50 | general 0.75 | discounted 0.38
*Key Findings:*:
    - Urticaria can worsen premenstrually, attributed to estrogen-driven mast-cell activation and relative progesterone withdrawal.
*Conclusion:*: Menstrual-cycle modulation of mast-cell disease is clinically recognised.
*Limitations:*: Review; urticaria focus; heterogeneous.

116 Kov{'a}cs and Larson 2006 — Mast-Cell Accumulation During Estrus

*Full Citation:*: Kov{\'a}cs KJ, Larson AA. Mast cells accumulate in the anogenital region of somatosensory thalamic nuclei during estrus in female mice. *Brain Research*. 2006;1114(1):85-97. [@Kovacs2006EstrusMastCell]
*DOI:*: [10.1016/j.brainres.2006.07.100](https://doi.org/10.1016/j.brainres.2006.07.100)
*PMID:*: 16949055
*Study Design:*: Animal (mouse) study.
*Certainty / population / discounted:*: raw 0.45 | animal 0.50 | discounted 0.23
*Key Findings:*:
    - Mast cells accumulate in CNS structures during estrus (the estrogen-dominant phase), showing cycle-dependent mast-cell trafficking.
*Conclusion:*: Mast-cell biology is cycle-sensitive at the tissue level.
*Limitations:*: Rodent; anatomical focus.

117 Ridolo et al. 2019 — Sex in Respiratory and Skin Allergies

*Full Citation:*: Ridolo E, Incorvaia C, Martignago I, Caminati M. Sex in Respiratory and Skin Allergies. *Clinical Reviews in Allergy \& Immunology*. 2019;56(3):322-332. [@Ridolo2019SexAllergies]
*DOI:*: [10.1007/s12016-017-8661-0](https://doi.org/10.1007/s12016-017-8661-0)
*PMID:*: 29306980
*Study Design:*: Review of sex differences in allergy/mast-cell disease.
*Certainty / population / discounted:*: raw 0.55 | general 0.75 | discounted 0.41
*Key Findings:*:
    - Female sex and hormonal cycles modulate allergy severity, including mast-cell-mediated skin and respiratory disease.
*Conclusion:*: Sex-hormone modulation of mast-cell disease is well documented and supports E4's plausibility.
*Limitations:*: Review; no ME/CFS-specific cycle-timing data.

118 Imhann et al. 2016 — Proton Pump Inhibitors Affect the Gut Microbiome

*Full Citation:*: Imhann F, Bonder MJ, Vich Vila A, Fu J. Proton pump inhibitors affect the gut microbiome. *Gut*. 2016;65(5):740-748. [@Imhann2016PPIMicrobiome]
*DOI:*: [10.1136/gutjnl-2015-310376](https://doi.org/10.1136/gutjnl-2015-310376)
*PMID:*: 26657899
*Study Design:*: Large observational cohort (n=1815) with replication.
*Certainty / population / discounted:*: raw 0.70 | general 0.75 | discounted 0.53
*Key Findings:*:
    - Acid suppression (PPI) shifts gut microbiome composition, enriching oral/GI taxa otherwise kept down by gastric acid.
*Conclusion:*: Acid suppression reliably alters the gut flora — the first link in the F1 chain.
*Limitations:*: PPI (not famotidine/H2RA) studied; composition, not histamine production, measured.

119 Vich Vila et al. 2020 — Impact of Commonly Used Drugs on the Gut Microbiota

*Full Citation:*: Vich Vila A, Collij V, Sanna S, Sinha T. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. *Nature Communications*. 2020;11:362. [@VichVila2020DrugsMicrobiota]
*DOI:*: [10.1038/s41467-019-14177-z](https://doi.org/10.1038/s41467-019-14177-z)
*PMID:*: 31953381
*Study Design:*: Population-scale metagenomics (n=1883).
*Certainty / population / discounted:*: raw 0.70 | general 0.75 | discounted 0.53
*Key Findings:*:
    - PPI (and to a lesser degree H2-receptor antagonists) alter gut microbiota composition and metabolic function.
*Conclusion:*: H2-receptor antagonists also affect the gut microbiome, supporting the F1 premise for famotidine.
*Limitations:*: Association; functional histamine output not directly quantified.

120 Barcik et al. 2017 — Immune Regulation by Histamine-Secreting Bacteria

*Full Citation:*: Barcik W, Wawrzyniak M, Akdis CA, O'Mahony L. Immune regulation by histamine and histamine-secreting bacteria. *Current Opinion in Immunology*. 2017;48:108-113. [@Barcik2017HistamineBacteria]
*DOI:*: [10.1016/j.coi.2017.08.011](https://doi.org/10.1016/j.coi.2017.08.011)
*PMID:*: 28923468
*Study Design:*: Review.
*Certainty / population / discounted:*: raw 0.55 | general 0.75 | discounted 0.41
*Key Findings:*:
    - Gut commensal bacteria can secrete histamine (histidine-decarboxylase-expressing taxa), which modulates host immunity and gut physiology.
*Conclusion:*: Bacterial histamine production is real and immunologically active — the second link in F1.
*Limitations:*: Review; no acid-suppression interaction data.

121 Mou et al. 2021 — Taxonomic Distribution of Histamine-Secreting Bacteria

*Full Citation:*: Mou Z, Yang Y, Hall AB, Jiang X. The taxonomic distribution of histamine-secreting bacteria in the human gut microbiome. *BMC Genomics*. 2021;22:695. [@Mou2021HistamineTaxonomy]
*DOI:*: [10.1186/s12864-021-08004-3](https://doi.org/10.1186/s12864-021-08004-3)
*PMID:*: 34563136
*Study Design:*: Genomic survey of histamine-producing taxa in the human gut.
*Certainty / population / discounted:*: raw 0.55 | general 0.75 | discounted 0.41
*Key Findings:*:
    - Histidine-decarboxylase genes are widespread across human gut bacteria, establishing which taxa can produce histamine.
*Conclusion:*: Confirms the machinery for bacterial histamine synthesis is present in the human gut.
*Limitations:*: Metagenomic potential, not measured histamine output.

122 De Palma et al. 2022 — Microbiota Histamine Drives Visceral Hyperalgesia via H4

*Full Citation:*: De Palma G, Shimbori C, Reed DE, Yu Y. Histamine production by the gut microbiota induces visceral hyperalgesia through histamine 4 receptor signaling in mice. *Science Translational Medicine*. 2022;14(656):eabj1895. [@DePalma2022MicrobiotaHistamineH4]
*DOI:*: [10.1126/scitranslmed.abj1895](https://doi.org/10.1126/scitranslmed.abj1895)
*PMID:*: 35895832
*Study Design:*: Animal (mouse) mechanistic study.
*Certainty / population / discounted:*: raw 0.65 | animal 0.50 | discounted 0.33
*Key Findings:*:
    - Microbial histamine production drives visceral pain via H4-receptor signaling, and is elevated in irritable-bowel-syndrome patients.
*Conclusion:*: Gut-bacterial histamine is functionally significant and can drive symptoms — the third (harm) link in F1.
*Limitations:*: Rodent mechanism + human IBS association; no acid-suppression arm.

123 Engevik et al. 2024 — Phylogenetically Diverse Bacteria Produce Histamine

*Full Citation:*: Engevik KA, Hazzard A, Puckett B, Hoch KM. Phylogenetically diverse bacterial species produce histamine. *Systematic and Applied Microbiology*. 2024;47(5):126539. [@Engevik2024BacteriaHistamine]
*DOI:*: [10.1016/j.syapm.2024.126539](https://doi.org/10.1016/j.syapm.2024.126539)
*PMID:*: 39029335
*Study Design:*: Microbial screening (in vitro culture).
*Certainty / population / discounted:*: raw 0.50 | in vitro 0.40 | discounted 0.20
*Key Findings:*:
    - Multiple phylogenetically diverse gut and environmental bacteria produce histamine in culture.
*Conclusion:*: Bacterial histamine production is phylogenetically widespread.
*Limitations:*: Culture-based; no host or pH interaction.

124 Lichtenstein and Gillespie 1973 — Histamine Release Inhibited by Histamine via H2 (Nature)

*Full Citation:*: Lichtenstein LM, Gillespie E. Inhibition of histamine release by histamine controlled by H2 receptor. *Nature*. 1973;244(5414):287-288. [@Lichtenstein1973H2Feedback]
*DOI:*: [10.1038/244287a0](https://doi.org/10.1038/244287a0)
*PMID:*: 4126784
*Study Design:*: In vitro (human leukocytes).
*Certainty / population / discounted:*: raw 0.60 | in vitro 0.40 | discounted 0.24
*Key Findings:*:
    - Histamine inhibits its own release from leukocytes via an H2-receptor negative-feedback loop.
*Conclusion:*: Establishes the autocrine negative-feedback brake that H2 blockade (famotidine) could remove.
*Limitations:*: In vitro; 1970s methodology; no clinical correlate.

125 Lichtenstein and Gillespie 1975 — H1 and H2 Antihistamines and Histamine Release

*Full Citation:*: Lichtenstein LM, Gillespie E. The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. *Journal of Pharmacology and Experimental Therapeutics*. 1975;192(2):441-450. [@Lichtenstein1975H1H2Release]
*PMID:*: 46921
*Study Design:*: In vitro (human leukocytes).
*Certainty / population / discounted:*: raw 0.55 | in vitro 0.40 | discounted 0.22
*Key Findings:*:
    - H2 antihistamines interfere with the histamine-mediated self-inhibition of histamine release.
*Conclusion:*: Direct demonstration that H2 blockade removes the feedback brake on mediator release.
*Limitations:*: In vitro.

126 Tung et al. 1982 — H2 Antihistamines Augment Antigen-Induced Histamine Release

*Full Citation:*: Tung R, Kagey-Sobotka A, Plaut M, Lichtenstein LM. H2 antihistamines augment antigen-induced histamine release from human basophils in vitro. *Journal of Immunology*. 1982;129(5):2113-2115. [@Tung1982H2AugmentRelease]
*PMID:*: 6181161
*Study Design:*: In vitro (human basophils).
*Certainty / population / discounted:*: raw 0.55 | in vitro 0.40 | discounted 0.22
*Key Findings:*:
    - H2 antihistamines (famotidine-class) AUGMENT antigen-induced histamine release from human basophils — the strongest direct support for F2's compensatory-harm premise.
*Conclusion:*: H2 blockade can increase, not decrease, mediator release — a mechanistically grounded harm signal.
*Limitations:*: In vitro basophils; no human dosing study confirms clinically significant compensation.

127 Masini et al. 1982 — H2-Receptor-Mediated Inhibition of Histamine Release

*Full Citation:*: Masini E, Blandina P, Brunelleschi S, Mannaioni PF. Evidence for H2-receptor-mediated inhibition of histamine release from isolated rat mast cells. *Agents and Actions*. 1982;12(1-2):85-88. [@Masini1982H2InhibitRelease]
*DOI:*: [10.1007/BF01965111](https://doi.org/10.1007/BF01965111)
*PMID:*: 6177221
*Study Design:*: In vitro (rat mast cells).
*Certainty / population / discounted:*: raw 0.50 | in vitro 0.40 | discounted 0.20
*Key Findings:*:
    - H2-receptor stimulation inhibits histamine release from mast cells, confirming the feedback brake in mast cells themselves.
*Conclusion:*: Corroborates the H2 autocrine brake at the mast-cell level.
*Limitations:*: Rodent mast cells; in vitro.

128 Contents

References

Alstadhaug, Karl Bjornar. 2014. “Histamine in Migraine and Brain.” Headache 54 (2): 246–59. https://doi.org/10.1111/head.12293.

Bissonnette, Elyse Y. 1996. “Histamine Inhibits Tumor Necrosis Factor Alpha Release by Mast Cells Through H2 and H3 Receptors.” American Journal of Respiratory Cell and Molecular Biology 14 (6): 620–26. https://doi.org/10.1165/ajrcmb.14.6.8652190.

Cowden, Jeffery M., Mai Zhang, Paul J. Dunford, and Robin L. Thurmond. 2010. “The Histamine H4 Receptor Mediates Inflammation and Pruritus in Th2-Dependent Dermal Inflammation.” Journal of Investigative Dermatology 130 (4): 1023–33. https://doi.org/10.1038/jid.2009.358.

Elenkov, Ilia J., Elizabeth Webster, Dimitris A. Papanicolaou, Thomas A. Fleisher, George P. Chrousos, and Ronald L. Wilder. 1998. “Histamine Potently Suppresses Human IL-12 and Stimulates IL-10 Production via H2 Receptors.” Journal of Immunology 161 (5): 2586–93.

Gibbs, Bernard F., and Francesca Levi-Schaffer. 2012. “H4 Receptors in Mast Cells and Basophils: A New Therapeutic Target for Allergy?” Frontiers in Bioscience (Landmark Edition) 17 (2): 430–37. https://doi.org/10.2741/3936.

Hu Frisk, Jun Mei, Lena Kjellen, Stephen G. Kaler, Gunnar Pejler, and Helena Ohrvik. 2017. “Copper Regulates Maturation and Expression of an MITF:tryptase Axis in Mast Cells.” Journal of Immunology 199 (12): 4132–41. https://doi.org/10.4049/jimmunol.1700786.

Jin, B. H., T. Hong, B. W. Yoo, C. O. Kim, D. Kim, Y. N. Kim, and M. S. Park. 2024. “Pharmacokinetics, Pharmacodynamics, and Safety of Izuforant, an H4R Inhibitor, in Healthy Subjects: A Phase i Single and Multiple Ascending Dose Study.” Clinical and Translational Science 17 (10): e70032. https://doi.org/10.1111/cts.70032.

Jutel, Marek, Mubeccel Akdis, and Cezmi A. Akdis. 2009. “Histamine, Histamine Receptors and Their Role in Immune Pathology.” Clinical and Experimental Allergy 39 (12): 1786–1800. https://doi.org/10.1111/j.1365-2222.2009.03374.x.

Jutel, Marek, Takeshi Watanabe, Sven Klunker, Mubeccel Akdis, Oliver A. Thomet, Jozef Malolepszy, Teresa Zak-Nejmark, et al. 2001. “Histamine Regulates t-Cell and Antibody Responses by Differential Expression of H1 and H2 Receptors.” Nature 413 (6854): 420–25. https://doi.org/10.1038/35096564.

Kadiyska, Tsvetana, Ivan Tourtourikov, Darina Madzharova, Samanta Ciurinskiene, Marta Savcheva, Ekaterina Ivanova-Todorova, Ralitsa Mileva-Popova, Radka Tafradjiiska-Hadjiolova, and Vanyo Mitev. 2025. “Impact of AOC1 and HNMT Variants on the Therapeutic Outcomes of a Histamine Reducing Diet in Autism Spectrum Disorder.” Journal of Molecular Neuroscience 75 (3): 105. https://doi.org/10.1007/s12031-025-02399-4.

Kilinc, Erkan, Ibrahim Ethem Torun, and Yasemin Baranoglu Kilinc. 2024. “Meningeal Mast Cell-Mediated Mechanisms of Cholinergic System Modulation in Neurogenic Inflammation Underlying the Pathophysiology of Migraine.” European Journal of Neuroscience 59 (9): 2181–92. https://doi.org/10.1111/ejn.15888.

Kupczyk, Maciej, and Piotr Kuna. 2017. “Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives.” Drugs 77 (12): 1281–94. https://doi.org/10.1007/s40265-017-0777-2.

Kutukova, N. A., A. S. Trulioff, A. V. Polevshchikov, and O. V. Shamova. 2025. “Dual Effects of Acetylcholine on Mast Cell-Nerve Interactions.” Doklady Biological Sciences 525 (1): 350–53. https://doi.org/10.1134/S001249662560054X.

Lakatos, Sara, and Judit Rosta. 2025. “Bidirectional Interplay Between Microglia and Mast Cells.” International Journal of Molecular Sciences 26 (15): 7556. https://doi.org/10.3390/ijms26157556.

Maintz, Laura, and Natalija Novak. 2007. “Histamine and Histamine Intolerance.” American Journal of Clinical Nutrition 85 (5): 1185–96. https://doi.org/10.1093/ajcn/85.5.1185.

Mehta, P., P. Miszta, P. Rzodkiewicz, O. Michalak, P. Krzeczynski, and S. Filipek. 2020. “Enigmatic Histamine Receptor H4 for Potential Treatment of Multiple Inflammatory, Autoimmune, and Related Diseases.” Life 10 (4): 50. https://doi.org/10.3390/life10040050.

Mishra, Neerad C., Jules Rir-sima-ah, R. Thomas Boyd, Shashi P. Singh, Sravanthi Gundavarapu, Raymond J. Langley, Seddigheh Razani-Boroujerdi, and Mohan L. Sopori. 2010. “Nicotine Inhibits Fc-Epsilon-RI-Induced Cysteinyl Leukotrienes and Cytokine Production Without Affecting Mast Cell Degranulation Through Alpha7/Alpha9/Alpha10-Nicotinic Receptors.” Journal of Immunology 185 (1): 588–96. https://doi.org/10.4049/jimmunol.0902227.

Murakawa, Tomohiro, Mamoru Suzuki, Keiichi Fukui, Tetsuya Masuda, Eiichi Mizohata, Ikuko Miyahara, Itaru Kurauchi, et al. 2025. “Real-Time Capture of Domain Movements During Copper Amine Oxidase Catalysis by Mix-and-Inject Serial Crystallography.” Nature Communications 16 (1): 11149. https://doi.org/10.1038/s41467-025-67230-5.

Ocak, Umut, Pinar Eser Ocak, Lei Huang, Weilin Xu, Yi Zuo, Ping Li, Marcin Gamdzyk, et al. 2020. “Inhibition of Mast Cell Tryptase Attenuates Neuroinflammation via PAR-2/P38/NF-kB Pathway Following Asphyxial Cardiac Arrest in Rats.” Journal of Neuroinflammation 17 (1): 144. https://doi.org/10.1186/s12974-020-01808-2.

Ohsawa, Yusuke, and Noriyasu Hirasawa. 2014. “The Role of Histamine H1 and H4 Receptors in Atopic Dermatitis: From Basic Research to Clinical Study.” Allergology International 63 (4): 533–42. https://doi.org/10.2332/allergolint.13-RA-0675.

Packard, K. A., and M. M. Khan. 2003. “Effects of Histamine on Th1/Th2 Cytokine Balance.” International Immunopharmacology 3 (7): 909–20. https://doi.org/10.1016/S1567-5769(02)00235-7.

Protasio Netto, Joao, Jose Fabio Lana, Andrea Parma, Fabio R. Costa, Roberto M. de Andrade, Marcos G. M. Castro, and Camilla Tambelli. 2026. “Is Histamine Intolerance a Treatable Subtype of Fibromyalgia? Evidence and Clinical Implications – Narrative Review.” Frontiers in Pain Research 7: 1786437. https://doi.org/10.3389/fpain.2026.1786437.

Qin, Bing, Yi Peng, Chenyu Zhong, Yang Cai, Shuai Zhou, Hu Chen, Jinjun Zhuang, et al. 2021. “Mast Cells Mediate Inflammatory Injury and Aggravate Neurological Impairment in Experimental Subarachnoid Hemorrhage Through Microglial PAR-2 Pathway.” Frontiers in Cellular Neuroscience 15: 710481. https://doi.org/10.3389/fncel.2021.710481.

Rentzos, Georgios, Anna Weisheit, Linda Ekerljung, and Jenny van Odijk. 2024. “Measurement of Diamine Oxidase (DAO) During Low-Histamine or Ordinary Diet in Patients with Histamine Intolerance.” European Journal of Clinical Nutrition 78 (8): 726–31. https://doi.org/10.1038/s41430-024-01448-2.

Schuschke, Dale A., Jack T. Saari, Crystal A. West, and Frederick N. Miller. 1994. “Dietary Copper Deficiency Increases the Mast Cell Population of the Rat.” Proceedings of the Society for Experimental Biology and Medicine 207 (3): 274–77. https://doi.org/10.3181/00379727-207-43816.

Walter, Miriam, Tim Kottke, and Holger Stark. 2011. “The Histamine H4 Receptor: Targeting Inflammatory Disorders.” European Journal of Pharmacology 668 (1-2): 1–5. https://doi.org/10.1016/j.ejphar.2011.06.029.

Wang, Chao, Hong Chen, Wei Zhu, Yuan Xu, Mengxin Liu, Lingjun Zhu, Fan Yang, et al. 2017. “Nicotine Accelerates Atherosclerosis in Apolipoprotein e-Deficient Mice by Activating Alpha7 Nicotinic Acetylcholine Receptor on Mast Cells.” Arteriosclerosis, Thrombosis, and Vascular Biology 37 (1): 53–65. https://doi.org/10.1161/ATVBAHA.116.307264.

Woestemeier, Anna, Tim Schwandt, Philipp Lingohr, Mariola Lysson, Sven Wehner, Joerg C. Kalff, and G. S. Hong. 2026. “Mast Cell Activation Within the Mesentery Depends on Vagal Signaling Following Abdominal Surgery.” Surgery Open Science 31: 44–53. https://doi.org/10.1016/j.sopen.2026.03.005.

Zybul, Pawel, Adam Przybylkowski, Oksana Wojas, and Boleslaw Samolinski. 2026. “Diamine Oxidase and Gastrointestinal Diseases.” Biomolecules 16 (8): 1136. https://doi.org/10.3390/biom16081136.